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ABSTRACT 
High-density lipoproteins (HDL) represent a spectrum of particles that have 
multiple cardioprotective functions. However, recent studies have suggested 
that plasma HDL-cholesterol (HDL-C) levels may not always predict HDL 
function. In recent years, acute, high-dose corticosteroid therapy has been 
associated with increased HDL-C levels, but little is known about the function 
of HDL in these subjects. The studies in this thesis investigate the effects of 
corticosteroid therapy in subjects with chronic obstructive pulmonary disease 
(COPD) on the size, composition, distribution and anti-inflammatory 
properties of HDL. 
Subjects with COPD were treated for 1 week with prednisone. Control 
subjects with lower respiratory tract infection were treated for 2 weeks with 
antibiotics. Blood was collected on days 1 and 5 after commencing 
treatment, and at 6 weeks post-treatment (baseline).  
Treatment of COPD subjects with prednisone increased plasma HDL-C and 
apolipoprotein (apo) A-I levels and decreased triglyceride levels but had no 
effect on circulating concentrations of apoA-II, apoB, total cholesterol or 
phospholipids. The treatment of lower respiratory tract infection subjects with 
antibiotics did not increase plasma HDL-C or apoA-I levels (Chapter 3).  
The influence of prednisone on the size, composition and sub-population 
distribution of HDL was investigated in Chapter 4. Prednisone treatment was 
associated with an increase in the total cholesterol content of HDL, as well 
as HDL particle size.  The change in HDL size in these subjects was 
associated with an increase in large apoA-I-, apoA-IV- and apoE-containing 
 V 
HDL particles. The observed changes in HDL size and composition during 
prednisone treatment were also associated with a concomitant reduction in 
cholesteryl ester transfer protein (CETP) activity. Antibiotic treatment, by 
contrast, decreased apoA-I and HDL total cholesterol levels, decreased HDL 
size and increased CETP activity.  
The results in Chapter 5 establish that HDL isolated from COPD subjects 
after 1 day and 5 days of treatment with prednisone inhibited expression of 
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion 
molecule-1 (VCAM-1) in vivo in cultured human coronary artery endothelial 
cells more effectively than control HDL isolated 6 weeks post-treatment. 
Additional studies confirmed that the anti-inflammatory effects of HDL from 
prednisone-treated subjects on ICAM-1 and VCAM-1 expression were not 
due to the association of prednisolone with HDL.  
The anti-inflammatory effects of prednisone also extended to plasma 
inflammatory markers (Chapter 6). Treatment with high-dose prednisone 
decreased circulating levels of monocyte chemoattractant protein-1 (MCP-1), 
soluble ICAM-1 (sICAM-1) and soluble VCAM-1 (sVCAM-1) in COPD 
subjects. Antibiotic treatment did not suppress the levels of these 
inflammatory markers. These results suggest that the mechanism for the 
inhibition of plasma proteins in prednisone-treated COPD subjects may be 
partially mediated by the anti-inflammatory actions of HDL.  
In conclusion, this thesis relates prednisone treatment in COPD subjects to 
changes in HDL structure and function. The studies provide evidence that 
high-dose prednisone therapy increases plasma HDL-C and apoA-I levels, 
and influences HDL sub-population distribution, size and remodelling, 
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possibly by inhibiting CETP. Furthermore, these studies establish that the 
HDL from prednisone-treated COPD subjects consist of large apoA-I-, apoA-
IV- and apoE-containing HDL particles that are known to be anti-
inflammatory in vitro, thus raising the possibility that the beneficial effects of 
corticosteroid treatment in people with COPD may be mediated, at least in 
part, by the anti-inflammatory properties of HDL.  
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 2 
INTRODUCTION 
There is compelling evidence from large-scale epidemiological studies that 
demonstrate the association of higher plasma high-density lipoprotein 
cholesterol (HDL-C) levels with lower cardiovascular risk1. High-density 
lipoproteins (HDL) have a number of well-characterised cardioprotective 
properties. The most extensively studied cardioprotective function of HDL 
relates to their participation in the reverse cholesterol transport pathway; the 
process whereby excess cholesterol is exported to HDL from peripheral 
cells, such as macrophages in the artery wall, and transported to the liver for 
excretion. HDL also have anti-inflammatory2,3, anti-oxidant4,5, anti-apoptotic6, 
anti-diabetic7,8 and anti-thrombotic9,10 properties. It is well recognised that 
plasma HDL levels are decreased in several pro-inflammatory and immune 
pathologies, including atherosclerosis11, inflammatory bowel disease12, 
rheumatoid arthritis13 and diabetes14,15.  
Synthetic corticosteroids, such as prednisone, are widely used to treat 
inflammatory diseases16. They reduce systemic inflammation by inhibiting the 
action of transcription factors and reducing pro-inflammatory gene 
transcription17. Current understanding of the effects of corticosteroid therapy 
on plasma HDL levels is limited and inconsistent. For example, treatment 
with acute, high-dose corticosteroids has been reported to increase plasma 
HDL-C levels, with low-density lipoprotein cholesterol (LDL-C) levels 
remaining either unchanged or elevated18-21. Prolonged administration of 
corticosteroids, by contrast, appears to increase LDL-C levels and decrease 
HDL-C levels22,23. More research is required to elucidate the mechanisms 
behind these physiological responses and identify the pathways involved in 
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each. 
The studies described in this thesis examine the effects of treating 
inflammatory pulmonary diseases with the synthetic corticosteroid, 
prednisone on plasma lipid and lipoprotein profiles, as well as HDL function 
and metabolism.  
Chronic obstructive pulmonary disease (COPD), either emphysema or 
chronic bronchitis, is characterised by increased plasma levels of 
inflammatory markers, including cytokines, chemokines and adhesion 
molecules, and is often treated with corticosteroids such as prednisone. Little 
is known about the effects of corticosteroids on lipoprotein metabolism, and 
HDL structure and function in people with COPD. The effects of prednisone 
treatment on HDL size, composition and sub-population distribution, as well 
as their anti-inflammatory properties, in subjects with COPD are the main 
focus of the studies in the subsequent chapters of this thesis.  
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1.1 Lipoproteins 
Plasma lipoproteins are water-soluble macromolecular complexes of lipids 
(triglycerides, unesterified cholesterol, esterified cholesterol and 
phospholipids) and various proteins, referred to as apolipoproteins24. Most 
plasma lipoproteins, contain a hydrophobic core of triglycerides and 
cholesteryl esters surrounded by a surface monolayer of phospholipids, a 
small amount of unesterified cholesterol and apolipoproteins25. In order of 
increasing density and decreasing diameter the lipoproteins in human 
plasma include; chylomicrons, very low-density lipoproteins (VLDL), 
intermediate-density lipoproteins (IDL), low-density lipoproteins (LDL) and 
HDL26.  
1.1.1 Lipoprotein classes 
Chylomicrons 
Chylomicrons are the largest (~1000 nm in diameter) and least dense 
(<1.006 g/mL) of all lipoproteins. They are triglyceride-rich (85-92%) 
lipoproteins with a diverse apolipoprotein cargo that are synthesised within 
the intestine. The apolipoproteins associated with chylomicrons include 
apolipoprotein (apo) A-I, apoA-II, apoB-48, apoC-I, apoC-II, apoC-III and 
apoE27. Chylomicrons transport dietary triglycerides and cholesterol from the 
intestine to non-hepatic tissues for utilisation or storage28.  
VLDL and IDL  
VLDL are approximately 25-90 nm in diameter and have a density ranging 
from 0.95 to 1.006 g/mL. They are triglyceride-rich lipoproteins that are 
secreted from the liver and contain several apolipoproteins, including apoB-
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100, apoC-I, apoC-II, apoC-III and apoE29,30. Hydrolysis of the triglyceride 
component of VLDL by lipoprotein lipase (LPL) results in the production of 
IDL31. IDL (25-35 nm in diameter) have a core consisting mainly of 
cholesteryl esters and some triglyceride, and float in the 1.006 g/mL to 1.019 
g/ml density range. Both VLDL and IDL transport triglycerides and 
cholesterol from the liver to peripheral tissues31.   
LDL 
Further hydrolysis of IDL by LPL generates LDL, which are 24-26 nm in 
diameter, with a density ranging from 1.019-1.063 g/mL32 and a core 
consisting almost entirely of cholesteryl esters33. The main protein 
component of LDL is apoB-10034-36.  
LDL transport cholesterol to peripheral tissues by binding to the LDL 
receptor. The binding of LDL to its receptor leads to four well-established 
events: 1) LDL is transferred into the cell by LDL receptor-mediated 
endocytosis37,38, 2) the cellular mechanism for cholesterol esterification is 
stimulated39, 3) the activity of hydroxymethylglutaryl-CoA reductase, the rate 
limiting enzyme involved in cholesterol synthesis, is suppressed40,41 and 4) 
the protein component of LDL is degraded42,43.  The accumulation of 
circulating oxidized LDL is associated with clinical manifestations of 
atherosclerosis44,45.  
HDL 
HDL are the smallest (7.6-10.6 nm diameter) and densest (1.063<d<1.25 
g/mL) of all lipoproteins. They predominantly originate as discoidal particles 
of apolipoproteins and phospholipids that are secreted into the plasma from 
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the liver46 but can also be assembled in the plasma from individual 
constituents47,48, or generated as products of the catabolism of triglyceride-
rich lipoproteins49. There is overwhelming evidence from human population 
studies that high HDL-C levels are an independent, inverse predictor of 
cardiovascular risk50,51. However, there is evidence that the cardioprotective 
properties of HDL may be ablated in certain conditions, including following an 
acute coronary syndrome event52. Whether this is can be attributed directly 
to changes in HDL particle size, or to other factors, is not yet known. 
Therefore, the association between HDL-C levels, HDL particle size and 
cardiovascular risk may not be as simple as originally anticipated. The 
structure, composition, synthesis and function of HDL are discussed in more 
detail in Sections 1.2-1.6.  
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1.2 Heterogeneity of HDL 
HDL in human plasma consist of multiple sub-populations of particles that 
vary in shape, density, size, protein composition and surface charge.  
1.2.1 Shape 
HDL can have either a spherical or discoidal morphology (Figure 1.1A). 
Discoidal HDL consist of a bilayer of phospholipid, a small amount of 
unesterified cholesterol and two or more apolipoprotein molecules. Spherical 
HDL particles consist of a surface monolayer of phospholipids, unesterified 
cholesterol and apolipoproteins that encapsulate a hydrophobic core of 
cholesteryl esters and some trigylceride4.   
1.2.2 Density 
HDL are classified on the basis of density into two main subfractions, HDL2 
and HDL3 (Figure 1.1B), which are isolated in the 1.063-1.125 g/mL and 
1.125-1.21 g/mL density range, respectively53. HDL3 are protein enriched 
particles that are smaller and denser than HDL254. HDL can also be further 
resolved by isopycnic density gradient centrifugation into five 
physiochemically defined, major HDL subfractions, HDL2b (1.085 g/mL), 
HDL2a (1.115 g/mL), HDL3a (1.136 g/mL), HDL3b (1.154 g/mL) and HDL3c 
(1.171 g/mL)53,55(Figure 1.1B).  
1.2.3 Size  
Non-denaturing gradient gel electrophoresis (GGE) has been used to 
characterise native human HDL on the basis of size. Five subclasses of HDL 
have been identified with this technique: HDL2b (10.6 nm), HDL2a (9.2 nm), 
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HDL3a (8.4 nm), HDL3b (8.0 nm) and HDL3c (7.6 nm)53,55,56 (Figure 1.1B). The 
identification of apoA-I containing sub-populations using two dimensional gel 
electrophoresis, which characterises HDL on the basis of size and charge, 
has indicated that HDL occupy an even broader size range, from 
approximately 5.6 to 14 nm in diameter57.  
1.2.4 Protein composition 
The major apolipoproteins of HDL are apoA-I (Mr 28.3 kDa) and apoA-II (Mr 
17.4 kDa), which comprise 70% and 20% of the total HDL protein, 
respectively58 (Figure 1.1C). HDL can be classified into two main populations 
on the basis of these apolipoproteins: 1) those that contain apoA-I without 
apoA-II, i.e. (A-I)HDL, and 2) those that contain both apoA-I and apoA-II, i.e. 
(A-I/A-II)HDL59 (Figure 1.1D). ApoA-I is approximately equally distributed 
between (A-I)HDL and (A-I/A-II)HDL, whereas the majority of apoA-II is 
associated with (A-I/A-II)HDL. The third and fourth most abundant HDL 
apolipoprotein after apoA-I and apoA-II are apoA-IV (Mr 46 kDa) and apoE 
(Mr 34.2 kDa)56,59,60.  HDL also contain a number of other apolipoproteins 
including apoC-I, apoC-II, apoC-III, apoC-IV, apoD, apoF, apoJ, apoL-1 and 
apoM61. Recently, proteomic techniques have also identified less abundant 
HDL-associated proteins with immune62, antioxidant63 and protease inhibitor 
functions61. The most recent studies of HDL structure and function have 
revealed yet another constituent transported by HDL, namely microRNAs 
(miRNAs), which mediate some of the biological effects of HDL64.  
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1.2.5 Surface charge 
HDL can also be separated on the basis of surface charge by agarose gel 
electrophoresis65. This technique classifies HDL as α-, pre-β- or γ-migrating. 
The most negatively charged HDL species are the α-migrating particles, 
followed by those that migrate to a pre-β position and those that migrate to a 
γ-position57. Most spherical HDL are α-migrating, while discoidal HDL and 
lipid-free apoA-I are pre-β migrating65,66. HDL that contain apoE as the only 
apolipoprotein migrate to a γ position67 (Figure 1.1D). The surface charge of 
HDL is determined by their surface phosphatidylinositol content and the 
conformation of their constituent apolipoproteins, which in turn is influenced 
by neutral lipid content and particle shape (discoidal or spherical)68.  
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Figure 1.1 The heterogeneity of HDL sub-populations  
HDL are classified according to their shape (A), density and size (B), 
composition (C) and surface charge (D). Figure adapted from Rye et al., 
200969.  
A 
B 
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1.3 Apolipoproteins: Synthesis, Structure and Function 
1.3.1 ApoA-I 
ApoA-I is the most abundant HDL apolipoprotein. It is a 243-amino acid, 
28.3-kDa polypeptide chain encoded together with apoA-IV, the C-
apolipoproteins and apoE as part of a multi-gene superfamily. The N- and C- 
terminal domains of apoA-I are involved in the binding of lipids70,71. 
Secondary structure analysis reveals that, aside from the 44-amino acid N-
terminal domain, apoA-I is organised into eight amphipathic α-helices of 22 
amino acids, and 11- and 22-mer repeats that are separated by proline 
residues72,73. This configuration allows the hydrophobic face of apoA-I to 
associate with phospholipids, while their hydrophilic polar face interacts with 
the aqueous environment and confers water solubility on the particles74-76. 
The N-terminal domain of apoA-I, which is highly conserved across species, 
is important for maintaining the compact conformation of apoA-I and is 
responsible for normal apoA-I function77.  
The average plasma apoA-I concentration in humans is 100-150 mg/dL78-81 
and approximate plasma half-life is 4 days82. There are three main sources 
of lipid-free apoA-I: (1) it is synthesized in the liver (~70%), where it enters 
the circulation and acquires phospholipids and unesterified cholesterol from 
cell membranes and other lipoproteins to form discoidal HDL83; (2) it is 
synthesized in the intestine (~30%), where it enters the circulation as a 
component of chylomicrons but dissociates during hydrolysis of chylomicron 
triglycerides by LPL84,85; (3) a small amount of apoA-I also dissociates from 
spherical, α-migrating HDL during remodelling by plasma factors86. 
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Approximately 5-10% of the apoA-I in normal human plasma exists in a lipid-
free/lipid-poor form66. Lipid-free apoA-I rapidly associates with phospholipids 
and unesterified cholesterol to produce discoidal particles, which can then be 
converted into spherical HDL by lectin-cholesterol acyltransferase (LCAT). 
There are several models proposed for the organisation of apoA-I in 
discoidal and spherical HDL. Discoidal HDL contain two apoA-I molecules, 
while spherical HDL contain two or more molecules of apoA-I66. Two models 
have been proposed for the arrangement of apoA-I proteins in discoidal HDL 
particles; 1) the ‘picket fence’ model where short helical segments of apoA-I 
are aligned parallel to the discoidal HDL phospholipid acyl chains87,88 and 2) 
the ‘double belt’ model, which suggests an anti-parallel arrangement of two 
apoA-I molecules wrapped around the circumference of discoidal 
HDL89,90(Figure 1.2A). Conversion of discoidal HDL into spherical HDL can 
change the ‘double belt’ structure into a ‘trefoil’ arrangement, with three 
apoA-I molecules arrange into identical conformations on the surface 
monolayer of the HDL(Figure 1.2B). With this arrangement, each of the 
cross-linking patterns and/or salt bridge interactions present within the 
discoidal particles are still present within the trefoil model91. The 
incorporation of an additional apoA-I molecule into HDL is believed to be 
achieved by LCAT-mediated HDL fusion or by direct incorporation of apoA-I 
into the HDL fraction92.  
As a major component of HDL, apoA-I plays a significant role in the reverse 
cholesterol transport process, where cholesterol is transported from 
peripheral tissues to the liver. Lipid-free/lipid-poor apoA-I is the key acceptor 
of cholesterol that is exported from peripheral cells in a process mediated by 
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the adenosine triphosphate-binding-membrane-cassette transporter A1 
(ABCA1)93. ApoA-I is the main activator of LCAT and is therefore important 
for promoting the esterification of discoidal HDL-cholesterol and the 
formation of spherical HDL94.  
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Figure 1.2 The ‘double belt’ and ‘trefoil’ models of (A-I) HDL from 
Silva et al., 200891 
a) The ‘double belt’ model suggests that two apoA-I molecules wrap around 
the circumference of discoidal HDL in an anti-parallel arrangement. b) The 
‘trefoil’ model suggests that three apoA-I molecules arrange into identical 
conformations on the surface monolayer of spherical HDL. Each putative 
helical domain is represented in a separate colour.  
A 
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1.3.2 ApoA-II 
ApoA-II is the second most abundant apolipoprotein of HDL. The human 
apoA-II gene is localised on chromosome 1. Human apoA-II has a molecular 
weight of 17.4 kDa and exists as a dimer of two 77-amino acid polypeptide 
chains covalently linked by a disulfide bridge24,95. ApoA-II has at least two 
lipid-associating domains consisting of three amphipathic helices that allow it 
to interact with the HDL surface96.  
The average concentration of apoA-II in normal human serum is between 30-
40 mg/dL97,98 and it has a half-life of approximately 4 days82. ApoA-II is 
produced in the liver and enters the circulation as a component of nascent 
HDL99. The high-lipid affinity of lipid-free apoA-II means that it rapidly 
acquires phospholipids and unesterified cholesterol from cell membranes 
and other lipoproteins to become discoidal in shape47. Discoidal (A-II)HDL 
are poor substrates for LCAT47,100 and as a result the majority of apoA-II in 
human plasma is found as a component of spherical (A-I/A-II)HDL. Two 
mechanisms have been suggested for the formation of apoA-II containing 
spherical HDL. The first involves the direct incorporation of lipid-free apoA-II 
into mature spherical (A-I)HDL, resulting in the displacement of apoA-I101,102. 
The second mechanism, facilitated by LCAT, involves the fusion of discoidal 
(A-II)HDL with small spherical (A-I)HDL103. 
ApoA-II has been shown to have pro-oxidant properties due to its ability to 
decrease paraoxonase 1 (PON1) enzymatic activity104. This may also explain 
the inability of HDL containing apoA-II to protect against LDL oxidation105. 
There is evidence that apoA-II also inhibit the cholesteryl ester transfer 
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protein (CETP)-mediated remodelling of HDL and prevent the dissociation of 
lipid-free apoA-I from the particles106.  
1.3.3 ApoA-IV 
Found on chromosome 11, ApoA-IV has a molecular weight of 46 kDa and 
consists of a 376-amino acid single polypeptide chain that lacks cysteine 
residues107,108. A polymorphism in the apoA-IV gene caused by the 
substitution of glutamine to histidine results in two isoforms, A-IV-1 and A-IV-
2109. Structural analysis reveals several 22-mer amino acid, amphipathic α-
helical repeats, which are responsible for the lipid-binding properties of 
apoA-IV107,110,111. Thirteen of these α-helical repeats form a single, large 
domain in the N terminus. This domain has been postulated to have weak 
lipid-binding characteristics as a consequence of: (1) the high hydrophilic and 
low amphipathic nature of the α-helices; (2) the α-helices being Y-type, which 
prevents them from penetrating deeply into lipid surfaces, and/or (3) the 
organisation of the α-helical hydrophobic regions makes them inaccessible to 
hydrophobic lipid interfaces. Furthermore, the C-terminal of apoA-IV lacks a 
lipid-binding domain and therefore has been found to inhibit lipid 
interactions107,110-112.  
ApoA-IV is present at an average concentration of 15 mg/dL in human 
plasma113,114. It is synthesised by enterocytes of the small intestine in 
response to lipid absorption and is secreted into mesenteric lymphatics as a 
component of nascent chylomicrons. Hydrolysis of chylomicron triglycerides 
by LPL generates an excess of surface constituents, which leads to the 
dissociation of apoA-IV. The newly released apoA-IV associates with HDL in 
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human plasma and also exists in a lipid-free form when dissociated from 
HDL115. 
ApoA-IV has anti-inflammatory and anti-oxidant properties. It inhibits P-
selectin transcription in colonic endothelium116, modulates the expression of 
myeloperoxidase, pro-inflammatory cytokines and reduces monocyte 
stimulation within the blood, liver, spleen and thymus116,117. ApoA-IV also 
protects lymphatic lipids and LDL from copper- and macrophage-mediated 
oxidation118.  
1.3.4 ApoE 
ApoE is a 34.2-kDa, 299-amino acid polypeptide localised on chromosome 
19. Within the plasma, apoE is found in chylomicrons, LDL, VLDL, IDL and 
HDL24,119. The presence of amphipathic α-helical lipid-binding domains 
enables apoE to switch between the lipid-free and lipoprotein-bound states. 
In the lipid-free state, apoE contains two independently folded domains with 
different functions. The amino-terminal domain contains a LDL receptor-
binding region while the carboxyl-terminal domain has a high affinity for 
lipid120,121. Three major apoE isoforms have been identified in human 
plasma: apoE2, apoE3 and apoE4122. ApoE3 is the most common isoform 
and is found in approximately 78% of the population. ApoE2, which is 
associated with type III hyperlipoproteinemia, differs from apoE3 at amino 
acid 158, where a cysteine residue is replaced by arginine122. ApoE4 has 
been linked to Alzheimer’s disease and differs from apoE3 at amino acid 
112, where an arginine residue is replaced by cysteine123.  
The plasma concentration of apoE in normolipidemic subjects is 3-7 mg/dL 
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but can be as high as 20-60 mg/dL in subjects with hyperlipidaemia24. The 
liver is the primary source of apoE but it is also synthesised by the spleen, 
kidney, adrenal gonads, brain, macrophages and astrocytic glia119. ApoE-
containing HDL levels are increased in CETP-deficient patients124.  
In humans, apoE-containing HDL generally do not contain other 
apolipoproteins, but those that do, contain apoE as well as apoA-I and/or 
apoA-II59,125,126. When subjected to non-denaturing gradient gel 
electrophoresis, these particles have been found to have a diameter ranging 
from 9 nm to 18.5 nm. Further analysis by two-dimensional gel 
electrophoresis has established that these particles have either γ, pre-β or α-
electrophoretic mobility59.   
1.3.5 ApoB 
ApoB is a non-exchangeable apolipoprotein that exists in two forms, apoB-48 
and apoB-100. ApoB-48 is synthesised in enterocytes and is a component of 
chylomicrons127. ApoB-100 is synthesised in the liver and incorporated into 
VLDL prior to secretion into the bloodstream127. As VLDL are converted into 
IDL and finally into LDL, apoB-100 remains associated with LDL particles to 
become the main apolipoprotein component these particles128,129. Both apoB-
100 and apoB-48 are products of a single gene located on human 
chromosome 2130,131. With 4536 amino acids, ApoB-100 is the largest 
apolipoprotein132. Structural analysis of mature apoB-100 has identified two 
polypeptide sequences that may be important in lipid binding. These regions 
consist of amphipathic α-helices and proline-rich hydrophobic sequences 
with β-sheet morphology, which are unique to apoB133,134. The primary 
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function of apoB is to act as a ligand for the LDL receptor and deliver 
cholesterol to peripheral tissues135. Lipoprotein(a) is an LDL-like particle that 
contains apoB (apoB100) and the disulphide linked apoa136. It synthesised in 
the liver by hepatocytes and is secreted into the plasma.  Circulating 
lipoprotein(a) levels are positively associated with CHD137.  
1.3.6 Other apolipoproteins 
ApoC-I, apoC-II and apoC-III associate with chylomicrons, VLDL and HDL. 
The liver is the main site of synthesis of the C apolipoproteins138. Peptide 
fragments of apoC-I have been shown to activate LCAT in vitro139. ApoC-II is 
a cofactor for lipoprotein lipase140. ApoC-III has been demonstrated to 
activate LCAT100, inhibit hepatic lipase141 and inhibit the activation of 
lipoprotein lipase142. The risk of coronary heart disease contributed by LDL 
has been found to result to a large extent from LDL that contain apoC-III143. 
The proatherogenic effects of apoC-III in VLDL and LDL are also extended to 
HDL that contain apoC-III144. 
ApoD is mainly expressed in the adrenal glands, kidneys, pancreas, 
placenta, spleen, lungs, ovaries, testes, brain, peripheral nerves and 
cerebrospinal fluid145. Within the plasma, apoD is mainly associated with 
HDL and forms disulfide-linked heterodimers with other lipoproteins146. While 
the functional role of lipoprotein-associated apoD remains unclear, its ability 
to form complexes with LCAT suggests that it may be involved in cholesterol 
esterification145,147.  
ApoF is a sialoglycoprotein that is synthesised in the liver and found on the 
surface of HDL and LDL148,149. It is also known as the lipid transfer inhibitor 
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protein (LTIP) and inhibits CETP-mediated cholesteryl ester and triglyceride 
transfer between lipoproteins150,151. ApoF is an important regulator of CETP 
function152. It has been found to inhibit transfer events involving LDL153, 
thereby increasing the transfer of cholesteryl esters from HDL to VLDL154. 
ApoJ (or clusterin) is distributed in a wide range of organs including the liver, 
brain, testis, ovary, heart, lung, spleen and mammary gland155. In plasma, 
apoJ associates with HDL and very high-density lipoproproteins (VHDL)156.  
Although the function of apoJ remains to be determined, it has been reported 
to be involved in sperm maturation157, complement inhibition158 and in 
cholesterol transport from peripheral tissues to the liver, when complexed to 
HDL containing apoA-I and apoE159.   
ApoL is found in plasma and a variety of tissues, including liver, lung, brain, 
pancreas, placenta and vascular endothelium160,161. The apoL gene cluster 
on chromosome 22 encodes for the six apoL proteins (apoL-I to apoL-VI) 
160,161. Plasma apoL levels correlate with triglyceride and HDL-C levels162. 
ApoL-1 associates mainly with large-diameter HDL particles163.  
The apoM gene is highly expressed in the human liver and kidney164. It is 
predominantly associated with HDL165. While the function of apoM is still to 
be determined, recent studies have shown that the subfraction of HDL 
containing apoM protects LDL from oxidation and mediates cholesterol efflux 
more efficiently than HDL lacking apoM165. ApoM-deficient mice form large 
HDL particles that are cholesterol enriched eventually become poor 
acceptors of cholesterol that efflux from macrophages. The conversion of 
HDL into pre-β HDL is also impaired and there is an increase in 
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atherosclerosis, which can be amended by the overexpression of apoM166.  
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1.4 Origins of HDL 
HDL originate as pre-β-migrating discoidal particles. The assembly of 
discoidal HDL requires the association of two or more lipid-free 
apolipoproteins with phospholipids and small amount unesterified 
cholesterol46. These constituents are either newly synthesized or dissociate 
from other particles.  
1.4.1 Origins of discoidal HDL 
The lipid-free apolipoproteins that are involved in HDL biogenesis are either 
produced by the liver or intestine or, dissociate from triglyceride rich 
lipoproteins that have undergone lipolysis by LPL167. The main HDL 
apolipoprotein, apoA-I, also originate by dissociating from mature spherical 
HDL that are being remodelled by various plasma factors168. HDL are formed 
in the liver when lipid-free apolipoproteins acquire the phospholipid and 
cholesterol that efflux from cells expressing the ABCA1169. Plasma 
apolipoproteins are also converted into discoidal HDL when they acquire 
phospholipids and unesterified cholesterol from peripheral cells that express 
ABCA1170.  
1.4.2 Origins of spherical HDL 
Discoidal HDL that acquire unesterified cholesterol are substrates for the 
enzyme LCAT, which catalyses the cholesterol esterification to form 
cholesteryl esters171. As cholesteryl esters are formed, they are sequestered 
into the centre of the HDL particles, converting discoidal HDL into small 
spherical HDL. These small spherical HDL particles are subsequently 
converted into larger, less dense HDL particles through the acquisition of 
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apolipoproteins and lipids from chylomicrons and VLDL that are undergoing 
lipolysis by LPL172. 
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1.5 HDL Remodelling  
HDL heterogeneity is a consequence of particle remodelling. Several plasma 
factors alter the size, shape, surface charge and composition of HDL. The 
factors responsible for these changes include LCAT, CETP, phospholipid 
transfer protein (PLTP), hepatic lipase (HL) and endothelial lipase (EL).  
1.5.1 LCAT 
LCAT is synthesized by the liver, with smaller concentrations produced by 
the brain and testes173. LCAT has phospholipase A2 and cholesterol 
acyltransferase activities. It catalyses the transfer of an acyl group from the 
sn-2 position of phosphatidylcholine to the free 3-β-hydroxyl group of 
unesterified cholesterol, generating cholesteryl esters and 
lysophosphatidylcholine174,175. This reaction accounts for the synthesis of 
most of the cholesteryl esters in human plasma174.   
LCAT is predominantly activated by apoA-I176,177, which gives LCAT access 
to phospholipids and cholesterol in HDL. The esterification of unesterified 
cholesterol in discoidal HDL generates cholesteryl esters that partition into 
the HDL core, converting discoidal HDL into mature spherical HDL171 (Figure 
1.5A). Discoidal (A-I)HDL are preferred as an LCAT substrate over spherical 
(A-I)HDL178 and small spherical (A-I)HDL are preferred over large spherical 
(A-I)HDL179. ApoA-IV and apoE also activate LCAT, but to a lesser extent 
than apoA-I, while apoA-II does not participate in the LCAT reaction171,180-183. 
Mutations in the LCAT gene result in either familial LCAT deficiency or fish-
eye disease184,185. Both of these conditions are characterised by low or 
undetectable LCAT levels, lack of esterification of HDL cholesterol in plasma, 
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the presence of predominantly discoidal HDL, and an absence of normal, 
spherical HDL184,185.   
1.5.2 CETP 
CETP is secreted from the liver as a 74-kDa hydrophobic glycoprotein that is 
mainly bound to HDL124,186. It mediates the transfer of cholesteryl esters from 
HDL to VLDL and LDL, and the transfer of triglycerides from VLDL to LDL 
and HDL187. Under circumstances where the transfer of cholesteryl esters 
from HDL to VLDL is greater than the transfer of triglycerides into HDL, the 
core lipid content of HDL decreases. This imbalance is rectified by the 
dissociation of lipid-free/lipid-poor apoA-I188 (Figure 1.3B). CETP can also 
remodel HDL into smaller particles via a fusion process and a structural 
rearrangement of the product which is not accompanied by the dissociation 
of lipid-free apoA-I189.  
Several mutations of the CETP gene have been identified as causes of 
CETP deficiency in humans190. Of particular interest, homozygous CETP 
deficiency has been associated with elevated concentrations of HDL-C, 
apoA-I, apoA-II and apoE191,192. These subjects also have reduced plasma 
LDL-C and apoB concentrations191.  
1.5.3 PLTP 
PLTP is an 81-kDa hydrophobic glycoprotein that circulates bound to HDL193. 
The main functions of PLTP are to catalyse the transfer of phospholipids 
between HDL and triglyceride-rich lipoproteins, and mediate the remodelling 
of HDL into large and small particles194. PLTP has been shown to increase 
HDL particle size by mediating HDL fusion and decrease HDL particle size 
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through the dissociation of lipid-free/lipid poor apoA-I195,196 (Figure 1.3C). 
Remodelling of this nature occurs more rapidly in triglyceride-rich HDL 
particles197. 
1.5.4 HL 
HL is a lipolytic enzyme, expressed mainly by the liver and bound to 
heparan-sulfate proteoglycans on the hepatic endothelium198. Hepatic 
triglyceride lipase is involved in the uptake of HDL by the liver199,200. HL then 
catalyses and hydrolyses phospholipids and triglycerides in HDL and 
triglyceride-rich lipoproteins. The remodelling of HDL by HL results in the 
loss of core lipids, a reduction in particle size and the dissociation of lipid-
free/lipid-poor apoA-I201,202 (Figure 1.3D). HL deficiency is characterised by 
elevated triglyceride content in LDL and HDL203.   
1.5.5 EL 
EL is an endothelial-cell derived lipolytic enzyme with high phospholipase 
and very low triglyceride lipase activity. The primary substrates of EL are 
HDL204,205. Studies with spherical, reconstituted HDL have established that 
EL mediates a modest reduction in HDL size without promoting the 
dissociation of lipid-free/lipid-poor apoA-I206 (Figure 1.3E). Over-expression 
of EL in mice decreases HDL cholesterol and apoA-I levels205,207. 
Conversely, inactivation of the EL gene in mice has been shown to increase  
1.5.6  ATGL 
Adipose triglyceride lipase (ATGL) is a triglyceride-specific lipolytic enzyme. 
ATGL is required for the movement of triglyceride in adipose tissue and non-
adipose tissues. The activity of ATGL is regulated by a network of hormones, 
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which control the availability of free fatty acids that may serve as energy 
substrates, precursors for other lipids, and lipid signalling molecules. The 
precise molecular mechanisms of ATGL activity an interaction with regulatory 
proteins are still to be determined and for this reason the impact of ATGL on 
HDL remodelling is currently unknown208. 
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Figure 1.3 Remodelling of HDL by plasma factors from Rye et al, 
200969 
(A) LCAT esterifies cholesterol on the surface of discoidal HDL. The resulting 
cholesteryl esters (CE) partition into the centre of the HDL particle to 
generate spherical HDL. (B) CETP mediates the transfer of CE from HDL to 
VLDL and LDL, and the transfer of triglyceride (TG) from VLDL to LDL and 
HDL. This remodels HDL into small particles and promotes the dissociation 
of lipid-free/lipid-poor apoA-I. (C) PLTP transfers phospholipids (PL) between 
HDL and VLDL and between different HDL sub-fractions. It remodels HDL 
into large and small particles and promotes the dissociation of lipid-free/lipid-
poor apoA-I. (D) HL hydrolyses PL and TG, remodels HDL into small 
particles and promotes the dissociation of lipid-free/lipid-poor apoA-I. (E) EL 
hydrolyses HDL PL and small amount of TG and remodels HDL into small 
particles.  
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1.6 HDL properties  
The functional properties of HDL particles have mainly been studied in the 
context of cardiovascular disease. HDL-C levels have been demonstrated to 
be an independent inverse predictor of coronary heart disease (CHD) risk51. 
The reverse cholesterol transport (RCT) pathway is one of the well-
established mechanisms by which HDL protect against atherosclerosis209. 
More recently, it has been demonstrated that HDL also possess anti-
inflammatory, antioxidant, anti-thrombotic and anti-apoptotic properties209.  
1.6.1 Reverse cholesterol transport 
The RCT pathway involves the HDL-mediated transfer of excess cholesterol 
from peripheral cells to the liver, where it is either excreted in bile or recycled 
back into the circulation as a component of newly synthesised lipoproteins210.  
The first step of RCT involves the efflux of phospholipids and unesterified 
cholesterol from cell membranes to lipid-free/lipid-poor apolipoproteins and 
discoidal, pre-β-migrating HDL particles. This process is driven by ABCA1211. 
When apoA-I acquires lipids via ABCA1, it is converted to discoidal HDL that 
are able to accept additional cholesterol that is being exported from cells by 
the ATP-binding cassette sub-family G member 1 (ABCG1) and ATP-binding 
cassette sub-family G member 4 (ABCG4)212,213 (Figure 1.4, step 1)  
Cholesterol that is effluxed to HDL by ABCA1 is rapidly esterified by LCAT 
(Figure 1.4, step 2). The esterification process promotes the conversion of 
discoidal HDL into large spherical particles, which dispose of their cholesteryl 
esters in a number of ways. Cholesteryl esters can be delivered directly to 
the liver via scavenger receptor-B1 (SR-B1)214 (Figure 1.4, step 3) or 
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transferred by CETP to VLDL and LDL (Figure 1.4, step 4), from where they 
are taken up by the liver via the LDL receptor for either excretion or de novo 
lipoprotein synthesis (Figure 1.4, step 5). Alternatively, the LDL and VLDL 
particles can transfer their cholesteryl esters to peripheral cells that require 
cholesterol215. 
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Figure 1.4 Reverse cholesterol transport pathway  
(1) Unesterified cholesterol is effluxed from peripheral cells via ABCA1 to 
lipid-free/lipid-poor apoA-I and pre-β HDL, or via ABCG1 and ABCG4 to 
spherical, α-migrating HDL. (2) The unesterified cholesterol on the surface of 
discoidal HDL is converted to cholesteryl esters (CE) by LCAT, generating 
spherical HDL. (3) HDL can deliver CE directly to the liver via SR-B1 for 
excretion or re-utilisation. (4) Alternatively, CE can be transferred to LDL and 
VLDL by CETP. (5) The CE in LDL and VLDL are taken up by the liver via 
the LDL receptor (LDLR). Dotted lines indicate the formation of discoidal 
HDL and VLDL in the liver. Figure adapted from Tan et al., 2009216.  
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1.6.2 Anti-inflammatory properties of HDL 
Inflammation is a complex immune response to vascular tissue injury217. 
Chronic inflammation underlies many human disorders, including COPD218, 
atherosclerosis219, rheumatoid arthritis220, osteoarthritis221 and psoriasis222. 
These inflammatory diseases differ in their mechanism of tissue insult but 
are systemically associated with elevated levels of inflammatory markers, 
such as C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), 
interleukin-1 (IL-1), interleukin-6 (IL-6) and monocyte chemoattractant 
protein-1 (MCP-1)217,223-225. In the case of endothelial cells, this inflammatory 
cascade up-regulates expression of the adhesion molecules, including 
intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-
1 (VCAM-1), P-selectin and E-selectin, which facilitate the attachment of 
monocytes to the endothelium. MCP-1 mediates the transmigration of 
monocytes across the endothelium where they are differentiated into 
macrophages by macrophage colony-stimulating factor (M-CSF)226,227.  
Numerous studies have provided evidence supporting the anti-inflammatory 
activity of HDL. Both in vitro and in vivo studies have shown that HDL inhibit 
inflammation by reducing the expression of ICAM-1, VCAM-1 and E-
selectin228-230. The molecular mechanism by which HDL inhibit adhesion 
molecule expression may partly be explained by the HDL-mediated inhibition 
of nuclear factor-κB (NF-κB) nuclear translocation. Furthermore, HDL inhibit 
the sphingosine kinase signal transduction pathway, which is critically 
important for endothelial cell activation and adhesion molecule expression231. 
HDL also inhibit the CRP-induced pro-inflammatory expression of endothelial 
cell adhesion proteins232. The anti-inflammatory properties of HDL have also 
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been linked to the inhibition of the pro-inflammatory chemokine, MCP-1, and 
its receptor, CCR2, thereby preventing monocyte recruitment into the 
subendothelial space233-235. Infusion of reconstituted HDL into humans with 
endotoxemia has been shown to decrease the plasma levels of TNF-α and 
IL-6236. Similarly, HDL isolated from human plasma has been shown to block 
T-lymphocyte-activated TNF-α production in monocytes237.  
1.6.3 Antioxidant properties of HDL 
Oxidative stress represents the imbalance that occurs when the rate of 
reactive oxygen species (ROS) production exceeds the rate of elimination by 
antioxidants238. ROS, which include superoxide anion (O2-), hydroxyl anion 
(OH-) and peroxynitrite (ONOO-), all contribute to the aetiology and 
progression of inflammatory diseases such as atherosclerosis and 
COPD239,240. Enzymatic sources of ROS include thioredoxin interacting 
protein (TXNIP)241, myeloperoxidase (MPO)242, nicotinamide adenine 
dinucleotide phosphate (NAPDH) oxidase243, cyclooxygenase (COX), 
lipoxygenase (LPO)244 and xanthine oxidase (XO)245.  
HDL contain a number of associated enzymes which contribute to its 
antioxidant properties, including paraoxonase-1 (PON-1), platelet-activating 
factor acetylhydrolase (PAF-AH) and glutathione phospholipid peroxidise5,246. 
The catalytic activities of PON and PAF-AH allow HDL to accept and 
inactivate oxidised phospholipids from cell membranes, as well as oxidised 
LDL247-249. HDL protect against LDL oxidation by removing cytotoxic 
phospholipid hydroperoxides from LDL. The hydroperoxides are 
subsequently inactivated by the methionine residues of apoA-I and apoA-
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II.4,250. Another key antioxidant function of HDL relates to its ability to inhibit 
the generation of ROS by decreasing superoxide synthesis and inactivating 
neutrophil and macrophage NADPH oxidase251-253.  
1.6.4 Anti-apoptotic properties of HDL 
HDL inhibit endothelial cell apoptosis in response to a number of stimuli, 
including oxidised LDL and TNF-α. Native HDL, as well as purified apoA-I, 
prevent cytosolic calcium and protease production in response to oxidised 
LDL and TNF-α, thereby protecting endothelial cells from apoptosis6,254. In 
vitro studies show that HDL also reduce pancreatic β-cell apoptosis255.  
1.6.5 Anti-thrombotic properties of HDL 
HDL have a number of anti-thrombotic actions, including increased blood 
flow256, decreased thrombin generation257 and inhibition of platelet 
activation258. HDL increases blood flow by enhancing nitric oxide (NO) 
generation by endothelial NO synthase (eNOS)256 and promoting 
prostacyclin synthesis259. HDL can reduce thrombus generation by 
upregulating endothelial cell thrombomodulin expression257 and enhancing 
protein S and activated protein C (APC) activity260. HDL also inhibit in vitro 
activation and aggregation of platelets by binding to the platelet surface 
directly258,261,262. HDL also impact on the coagulation cascade by inhibiting 
synthesis of tissue factor in endothelial cells263.   
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1.7 Inflammatory pulmonary disease 
Inflammation may be classified as either acute or chronic. Acute 
inflammation refers to the rapid onset and resolution of the immune response 
while, chronic inflammation occurs over a prolonged period of time and is 
characterised by continuous tissue destruction and repair264,265. Generally, 
inflammation is attributed to the local accumulation of leukocytes, plasma 
proteins and fluid (edema), caused by vasodilation at the site of injury266.  
However, many chronic diseases, manifest the inflammatory response 
through the systemic circulation267. For instance, the systemic features of 
skeletal muscle dysfunction268, cardiovascular disease269, osteoporosis270 
and diabetes271 are similar to the inflammatory pathophysiology of 
COPD267,272. 
1.7.1 Pulmonary inflammation in COPD 
COPD includes a collection of progressive inflammatory disorders of the 
central peripheral airways (bronchioles) and lung parenchyma that obstruct 
airflow. These conditions include chronic bronchiolitis, emphysema and 
chronic bronchitis273. Several inflammatory cell types and mediators are 
increased and/or activated in the airways of COPD patients. The 
inflammatory cells that are increased include neutrophils, macrophages, T 
lymphocytes, eosinophils and epithelial cells. The inflammatory mediators 
include leukotrienes, prostaglandins, platelet-activating factor, ROS, 
chemokines, cytokines, growth factors, endothelins, neuropeptides and 
proteinases274.  
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Increased numbers of activated neutrophils are found in sputum and 
bronchoalveolar lavage fluid (BALF) of patients with COPD275,276. Neutrophils 
move into the airways or parenchyma by adhering to endothelial cells in 
which expression of E-selectin and ICAM-1 is increased277,278. These 
neutrophils are believed to contribute to parenchymal destruction by 
secreting several proteinases, including neutrophil elastase and cathepsin 
G279.  
COPD patients also show increased numbers of macrophages in their 
airways, lung parenchyma, BALF and sputum280,281. They are recruited from 
circulating monocytes by MCP-1 and phagocytise apoptotic neutrophils and 
endothelial cells282. These macrophages release TNF-α, IL-8 and leukotriene 
B(4) (LTB4), which increase the inflammatory response274. There is a direct 
correlation between macrophage numbers in the airways and COPD 
severity283.  
The main chemokines released into the sputum and BALF in COPD are IL-8, 
MCP-1, and the macrophage inflammatory proteins-1α (MIP-1α), and MIP-
1β. IL-8, a chemoattractant for neutrophils, is also present in high 
concentration in the sputum of COPD patients284,285. MCP-1 and MIP-1β are 
both increased in BAL fluid of these patients286. Macrophage activation in 
smokers has been attributed to MIP-1α, which shows increased expression 
in airway epithelial cells of patients with pulmonary inflammation287.  
Cytokines such as TNF-α and granulocyte macrophage-colony stimulating 
factor (GM-CSF) are important inflammatory mediators of COPD. TNF-α is 
present in high concentration in bronchial biopsies288 and BAL fluid of COPD 
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patients285. It activates the transcription factor NF-κB, which increases the 
transcription of pro-inflammatory genes, including IL-8 in macrophages and 
epithelial cells289,290. GM-CSF is also elevated in the BAL fluid of stable 
COPD patients and is markedly increased during exacerbations291.  
1.7.2 Pulmonary oxidation in COPD 
Oxidative stress, which is considered to be a major factor in the 
pathogenesis of COPD, is characterised by increased concentrations of ROS 
and reactive nitrogen species (RNS) in the lungs292,293. The respiratory 
epithelium is the major defensive barrier against ROS and RNS as it contains 
several antioxidant species, including superoxide dismutase (SOD), 
glutathione peroxidise, ascorbic acid (vitamin C) and α-tocopherol (vitamin 
E)294. In spite of these well-developed antioxidant defense systems, the 
increased oxidant burden in COPD creates an oxidant/anti-oxidant 
imbalance295. Redox stress often leads to oxidative damage of DNA, lipids 
and proteins. It can also activate NF-κB in pulmonary cells, resulting in an 
exacerbation of inflammation296.  The main oxidative stress markers in 
COPD patients, as demonstrated by exhaled breath condensate (EBC), 
include hydrogen peroxide (H2O2), nitric oxide (NO) and 8-isoprostane297-299. 
The principal endogenous sources of oxidants in the respiratory tract include 
alveolar macrophages, epithelial cells, endothelial cells and recruited 
inflammatory cells such as neutrophils, eosinophils, monocytes and 
lymphocytes300. Activation of these cells results in the formation of 
superoxide anion (O2-) via the NADPH oxidase and XO pathways301. O2- is 
rapidly converted to H2O2 by SOD302. Excess NO, produced presumably via 
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inducible NO synthase (iNOS), also reacts rapidly with O2-, and results in the 
formation of the highly pro-inflammatory molecule, peroxynitrite303. 
Furthermore, products of lipid peroxidation, such as thiolbarbituric acid 
reactive species are increased in COPD patients297.  
ROS mediated peroxidation of arachidonic acid produces isoprostanes. 
Patients with chronic pulmonary disease have elevated levels of 8-
isoprostane in the EBC304 that positively correlate with the percentage of 
neutrophils in patient sputum, indicating that oxidative stress may have a 
positive modulatory effect on inflammation in COPD299.  
1.7.3 Systemic features of COPD 
The detrimental effects of COPD extend beyond the lungs and have several 
systemic manifestations that have been attributed to increased plasma levels 
of oxidative and inflammatory markers. In addition, COPD is associated with 
other diseases, such as osteoporosis, cardiovascular diseases, diabetes and 
metabolic syndrome, suggesting that these comorbidities may have a 
systemic link305,306.  
How and why individuals with COPD develop systemic inflammation is 
unknown. It is predicted that in some cases, the inflammatory process in the 
lungs may “spill over” into the systemic circulation, promoting a generalised 
inflammatory reaction307,308. 
Plasma levels of several cytokines, including TNF-α and its soluble receptor, 
IL-6 and IL-8, as well as acute phase proteins, such as C-reactive protein 
(CRP), serum amyloid A and fibrinogen are increased in patients with 
COPD309,310. TNF-α concentrations have been correlated with disease 
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severity when analysed in stable patients and in those with an 
exacerbation311. Furthermore, circulating monocytes harvested from COPD 
patients have been shown to secrete more TNF-α than those from healthy 
controls312. Together, these studies provide evidence of the central role of 
TNF-α in both lung and systemic inflammation.  
Acute exacerbation of COPD is also associated with increased systemic 
levels of IL-6, which stimulates hepatic fibrinogen production. Fibrinogen is 
an independent risk factor for CHD and thereby provides a potential 
mechanism linking respiratory infection to risk of cardiovascular morbidity 
and mortality313. Another important inflammatory marker of COPD, which is 
also regulated by IL-6, is CRP. Individuals with serum CRP levels >3 mg/L 
have an increased incidence of COPD hospitalisation and death314.  
Oxidative stress plays a key role in the pathogenesis of COPD. The impaired 
antioxidant status of pulmonary disease has been investigated both locally 
and systemically. Systemic markers of oxidative stress in COPD patients 
include the lipid peroxidation proteins; XO315 and erythrocyte glutathione 
peroxidase (GPx)316,317 and the oxidative damage marker; coenzyme Q10296. 
The lipid peroxidation enzyme XO, which is associated with increased free 
radical generation of O2- and H2O2, is increased in the plasma of COPD 
subjects315. In contrast, the decreased antioxidant activity of erythrocyte GPx 
is associated with high serum levels of the lipid peroxidation product, 
malondialdehyde (MDA), which has been linked to COPD severity316.  
Increased plasma levels of oxidised Coenzyme Q10 in patients with COPD 
have been attributed to increased levels of systemic oxidative stress296. 
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Systemic oxidative stress has also been reported in peripheral blood 
neutrophils obtained from patients during acute exacerbations of COPD. The 
neutrophils from these patients show increased production of the superoxide 
anion, but function normally when the patient has returned to a stable 
state318. 
1.7.4 Pulmonary inflammation and lipids 
Inflammation is associated with disruptions to lipid metabolism. During 
inflammatory state, plasma levels of HDL-C, LDL-C, apoA-I, apoB and total 
cholesterol are reduced, while triglyceride levels are increased319-323. Low 
lipid concentrations are found in critically ill patients as well as in people with 
infections and sepsis323,324. Furthermore, lower plasma cholesterol 
concentrations correlate with higher levels of pro-inflammatory cytokines, 
increased mortality risk, development of nosocomial infection and organ 
dysfunction320,322,325.  
Acute inflammation is associated with compositional changes in HDL that 
include enrichment with the acute phase protein, serum amyloid A (SAA)326. 
This remodels HDL into larger, more dense particles that are depleted of 
apoA-I327. The incorporation of SAA into HDL particles does not compromise 
the functional properties of HDL328. Acute inflammation has also been 
associated with increased catabolism of HDL. During inflammation, secretory 
group IIa phospholipase A(2) (sPLA(2)), a cytokine-induced acute phase 
enzyme has also been shown to hydrolyse HDL phospholipids and increase 
SR-B1-mediated selective cholesteryl ester uptake329.  
	   CHAPTER ONE 
 
 42 
Corticosteroids such as prednisone are often used for the treatment of 
pulmonary inflammation and are documented to induce significant changes 
in the lipids profiles of these subjects330 (discussed below). 
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1.8 Prednisone 
Prednisone and its active metabolite, prednisolone, are synthetic 
corticosteroids with high glucocorticoid and low mineralocorticoid activity. 
Prednisone is an effective immunosuppressant that is used in a wide range 
of autoimmune disorders, inflammatory diseases and organ transplant 
operations331,332.  
1.8.1 Efficacy and indications 
Naturally occurring glucocorticoid hormones such as hydrocortisone are 
synthesized in the adrenal cortex and secreted into the blood to support a 
variety of immune, cardiovascular, metabolic and homeostatic functions. The 
levels of glucocorticoids in the circulation fluctuate in a circadian mode333. 
Synthetic glucocorticoids have been developed for use in a number of auto-
immune and inflammatory disorders including COPD334, rheumatoid 
arthritis335, Crohn’s disease336, multiple sclerosis337, leukaemia338 and 
hepatitis339.  Prednisolone is also an effective immunosuppressant in organ 
transplantation340 and in adrenal insufficiency syndromes such as Addison’s 
disease341.  
Glucocorticoid use is associated with a number of adverse side-effects. 
Short-term use can lead to fluid retention, euphoria, insomnia and increased 
blood glucose levels. Long-term use is associated with the development of 
osteoporosis, Cushing’s syndrome and diabetes mellitus342. A major 
drawback of glucocorticoid use is its ability to cause adrenal suppression. 
Exogenous glucocorticoids cause feedback inhibition of both corticotrophin-
releasing hormone (CRH) from the hypothalamus and adrenocorticotropic 
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hormone (ACTH) from the anterior pituitary343.  
1.8.2 Pharmacokinetics and bioavailability of prednisone and 
prednisolone 
Prednisone is considered to be an inactive molecule until it is absorbed from 
the gastrointestinal tract and converted to its active metabolite prednisolone, 
by hydrogenation of the ketone group, in the liver. The preconversion half-life 
of prednisone is approximately 1 hour344,345. The plasma half-life of 
prednisolone following the oral administration of prednisone ranges from 2.5 
to 3.5 hours346-348, which is similar to the half-life of orally administered 
prednisolone346,349,350. Greater than 90% of the orally or intravenously 
administered prednisolone can be recovered in the urine as free or 
conjugated metabolites351.  
1.8.3 Anti-inflammatory and antioxidant actions of glucocorticoids 
Glucocorticoids exert their anti-inflammatory effects by diffusing readily 
across cell membranes and binding to glucocorticoid receptors (GR) in the 
cytoplasm. GR are expressed in almost all cell types and are normally bound 
to molecular chaperones, such as heat shock protein-90 (hsp-90) and FK-
binding protein. These proteins prevent the nuclear localisation of 
unoccupied GR352. The human GR is encoded by a single gene but exists as 
several variants due to mutations and/or polymorphisms, alternative splicing 
of transcript and alternative translation initiation353. Alternative splicing of the 
GR primary transcript generates two isoforms, GRα and GRβ354. GRα binds 
corticosteroids while GRβ binds to DNA.  Binding of glucocorticoids to GRα 
results in the dissociation of the molecular chaperone355,356. The activated 
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GR-steroid complex then rapidly translocates into the nucleus where it binds 
to glucose-response elements (GREs) including steroid-receptor coactivator-
1 (SRC-1) and cyclic AMP response element-binding protein (CREB)-binding 
protein (CBP), in the promoter region of steroid-sensitive genes, leading to 
gene transcription or suppression (Figure 1.5)357-361. Selected genes that are 
directly regulated by glucocorticoids are shown in Table 1.1.  
Several genes such as annexin-1 and IκB-α362 are switched on by 
glucocorticoids. These genes either have anti-inflammatory effects or affect 
the inflammatory signal transduction pathway. When mitogen-activated 
protein (MAP) kinase phosphatase-1 (MKP-1) is activated, it inhibits p38 
MAP kinase363 and glucocorticoid-induced leucine zipper protein (GILZ), 
which inhibits both activator protein-1 (AP-1) and NF-κB364 (Figure 1.5).  
Less commonly, GR-steroid complex homodimers bind to negative GREs to 
suppress the expression of genes that cause the adverse side-effects 
associated with glucocorticoid use (Figure 1.5). Inappropriate regulation of 
these genes is linked to the development of osteoporosis, growth retardation 
in children, skin fragility and metabolic effects365. 
The major anti-inflammatory effects of glucocorticoids are through repression 
of inflammatory and immune genes. This is believed to occur when GR-
steroid complexes bind to inflammatory transcription factors, such as AP-1 
and NF-κB, and inhibit the expression of genes encoding for cytokines, 
chemokines, inflammatory enzymes, adhesion molecules and inflammatory 
receptors17,366, including GM-CSF, MIP-1α, RANTES (regulated on 
activation, normal T cell expressed and secreted), eotaxin, TNF-α, IL-1β, IL-
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3, IL-5, IL-6, IL-8, IL-11, IL-12 and IL-13367,368. Many cytokine and chemokine 
gene promoters do not contain a negative GRE. Therefore, the down-
regulation of these genes is believed to be mediated by cross-signalling of 
glucocorticoids with critical transcription factors, mainly AP-1 and NF-κB369.  
A number of enzymes that mediate both inflammation and oxidative stress 
are inhibited by glucocorticoids. Both in vitro and in vivo studies have 
established that glucocorticoids can inhibit iNOS mRNA expression370-373. 
Glucocorticoids also inhibit the cytokine-induced expression of 
phospholipase A2 within glomerular mesangial cells374 and COX-2 within 
pulmonary epithelial cells, which in turn reduce prostaglandin and 
thromboxane synthesis375. 
The cytokine-induced expression of adhesion molecules in endothelial, 
epithelial and inflammatory cells is also decreased by glucocorticoids. It has 
been shown that the expression of E-selectin, ICAM-1 and endothelial 
leukocyte adhesion molecule is down-regulated by corticosteroids376, as is 
the basal and cytokine-stimulated ICAM-1 expression in human bronchial 
epithelial cells377,378. 
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Figure 1.5 Anti-inflammatory actions of corticosteroids  
Corticosteroids diffuse into the cell, bind to GR in the cytoplasm and 
translocate into the nucleus. Within the nucleus, corticosteroids regulate 
gene expression in several ways. GR homodimers bind GREs in the 
promoter region of steroid sensitive genes, which leads to the transcription of 
inflammatory genes. Less commonly, GR homodimers interact with negative 
GREs to suppress gene transcription, especially those linked to the side-
effects of corticosteroids. Single GR-steroid complexes interact with 
coactivator molecules such as CBP, switching off the expression of 
inflammatory genes. Figure adapted from Barnes, P.J., 2006379. 
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Table 1.1 List of glucocorticoid-sensitive genes  
Down-regulated transcription Increased transcription 
Chemokines 
IL-8, RANTES, macrophage 
Inflammatory protein-1α, monocyte 
chemoattractant protein (MCP)-1, 
MCP-3, MCP-4, eotaxin 
 
Cytokines 
Interleukins-1, 2, 3, 4, 5, 6, 9, 11, 12, 
13, 16, 17, 18, TNF-α, granulocyte 
macrophage colony-stimulating 
factor, stem cell factor 
 
Inducible enzyme 
Inducible nitric oxide synthase, 
cyclooxygenase-2, cytoplasmic 
phospholipase A2 
 
Endothelin-1 receptors 
Neurokinin NK1-receptors, NK2-
receptors 
 
Adhesion molecules 
Intercellular cell adhesion molecule-
1, E-selectin 
 
Lipocortin-1/annexin-1 
(phospholipase A2 inhibitor) 
 
Clara cell protein (CC10, 
phospholipase A2 inhibitor) 
 
β2-adrenoceptor 
 
Secretory leukocyte inhibitory protein 
(SLPI) 
 
IL-1 receptor antagonist 
 
IL-1R2 (decoy receptor) 
 
IκBα (inhibitor of NF-κB) 
 
CD163 (scavenger receptor) 
 
MAP Kinase phosphatase 1 (MKP-1) 
 
Table adapted from Hayashi et al., 2004362 
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1.8.4 Prednisone and plasma lipids 
Corticosteroids such as prednisone have been reported to exert marked 
effects on plasma lipoprotein metabolism. However, there are few studies on 
the nature and extent of these changes in humans and the results are 
conflicting. Acute corticosteroid treatment is reported to increase plasma total 
cholesterol, HDL-C and VLDL levels, while triglyceride and LDL-C levels are 
reported to be unchanged in some studies, but elevated in others18,20,21,23,380. 
The increase in HDL-C levels have been attributed to an increase in the 
HDL2 subfraction21.  
The long-term administration of corticosteroids is reported to increase 
plasma triglyceride and LDL-C levels and decrease HDL-C levels19,22,381,382. 
Conversely, prednisone withdrawal in kidney transplant patients is 
associated with decreased plasma HDL-C and apoB concentrations, while 
triglyceride and LDL-C levels are unaffected383.  Chronic, high-dose use of 
prednisone in renal transplant recipients is associated with decreased levels 
of lipoprotein(a)384,385. 
Current understanding of the impact of corticosteroids on plasma 
apolipoprotein levels and function is also limited and inconsistent. Short-
term, high-dose administration of prednisone to healthy individuals has been 
reported not to change plasma apoA-I, apoA-II, apoB and apoE levels in one 
study18 while decreasing apoA-II levels in another21.  
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1.9 Scope of this thesis 
This thesis is concerned with extending current knowledge of plasma lipid 
and lipoprotein profiles in subjects with chronic inflammatory pulmonary 
diseases that have been treated with prednisone. The effects of prednisone 
treatment on anti-inflammatory properties of HDL, HDL composition and the 
remodelling of HDL by CETP are also investigated.  
The main aims are:  
(i) To elucidate the effects of prednisone on the lipid and lipoprotein 
profiles of subjects with chronic inflammatory pulmonary disease. 
(ii) To quantify prednisone-induced changes in size, composition and 
sub-population distribution of HDL in subjects with chronic 
inflammatory pulmonary disease.  
(iii) To investigate the effects of prednisone on the anti-inflammatory 
properties of HDL in subjects with inflammatory pulmonary disease. 
(iv) To determine the effects of prednisone on systemic inflammatory 
markers in subjects with pulmonary inflammation.  
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MATERIALS AND METHODS  
2.1 Subjects 
Patients were aged between 18 and 80 years. The treatment group (n=16) 
consisted of subjects with an infective exacerbation of COPD. These patients 
received acute, high-dose, orally administered prednisone (50 mg/day over 5 
days).  To prevent adrenal suppression, the dosage of prednisone was 
gradually reduced after 5 days of treatment. The control group (n=7) 
consisted of patients with lower respiratory tract infections treated for 14 
days with antibiotics (augmentin, klacid, rulide or amoxil). Both groups were 
recruited into the study from the Respiratory and Emergency Departments of 
Royal Prince Alfred Hospital, Sydney. Statistical power calculations indicate 
that a total of 16 COPD and 7 control subjects in this two-treatment parallel-
designed study would provide 97.9% and 99.3% probability to detect 35% 
and 25% treatment difference respectively at a two-sided 95% confidence 
interval.  
The antibiotic treated, lower respiratory tract infection patient arm to this 
project was included as a comparator group to validate the changes in 
lipoproteins in prednisone treated subjects. The lower respiratory tract 
infection patients have a similar disease profile to COPD patients with 
treatment being the only variable. The antibiotic treated group therefore 
provides a relevant comparison to the effects that were observed on HDL 
structure and function in the prednisone treated group.  
The exclusion criteria included use of corticosteroids two months prior to 
recruitment, use of lipid-lowering drugs (including statins), diabetes, HIV 
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infection, hepatitis B and hepatitis C. Patients with known history of lipid 
disorders were also excluded from the study. This included subjects with 
abnormally elevated levels of any or all lipids and/or lipoproteins 
(hypercholesterolaemia, hyperlipidaemia and hypertriglyceridaemia).  
Normality was based on total cholesterol levels <5.2 mmol/L, triglyceride 
<2.0 mmol/L, HDL-C of 1-2.5 mmol/L and LDL-C <3.5 mmol/L. 
All treatments and pathology collection procedures were performed in 
accordance with the guidelines and regulations of the Sydney South West 
Area Health Service (SSWAHS) Human Ethics Committee. The approved 
ethics protocol number is X09-0047. 
The development of this thesis represents interaction between my 
supervisors and myself. The clinical samples were collected by the 
respiratory physician, Dr. Edmund Lau at Royal Prince Alfred Hospital, after 
which all experimental procedures were conducted by myself. My input in all 
levels of this thesis; aims, experimental design, development and 
statistical/results analysis were substantiated and decisions about how to 
proceed were my own.   
2.2 Blood collection and plasma isolation 
Three 20-mL blood samples were collected from all patients: (i) on day 1 
(approximately 24 hours after commencing treatment), (ii) on day 5 of 
treatment or upon discharge from hospital and (iii) at 6 weeks post-treatment. 
Values obtained from analysis of the 6-week sample are regarded as no-
treatment baseline values. Blood was collected in ethylenediaminetetraacetic 
acid (EDTA)-Na2 vacuette tubes and plasma was isolated by centrifugation 
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at 3,000 rpm for 10 minutes at room temperature. Plasma was stored at 4oC 
for up to 1 day until further analysis.  
2.3 Isolation of HDL by sequential ultracentrifugation 
HDL were isolated from plasma by sequential ultracentrifugation as 
previously described by Havel et al386. This procedure was carried out at 4oC 
using a Beckman 100.4 Ti rotor in a Beckman TL-100 bench-top 
ultracentrifuge (Beckman Instruments, Fullerton, CA, USA). Approximately 8 
mL of EDTA-Na2 plasma from each sample was adjusted to a density of 
1.063 g/mL with solid potassium bromide (KBr), sealed in 100.4 Ti plastic 
tubes with a capacity of 5.1 ml each, and ultracentrifuged at 100,000 rpm for 
16 hours at 4oC. The ρ>1.063 g/mL fraction was collected by tube slicing, 
adjusted to a density of 1.25 g/mL with KBr and spun at 100,000 rpm for 16 
hours at 4oC. The ρ<1.25 g/mL fraction was collected by tube slicing, 
dialysed for 3-4 hours against a 1.25 g/mL KBr density solution (1L) 
containing EDTA-Na2 (100 mg/L) and NaN3 (200 mg/L), and then subjected 
to a further 16 hours of ultracentrifugation at 100,000 rpm. The ρ<1.25 g/mL 
fraction was again collected by tube slicing and dialysed against 0.01 M/L 
endotoxin-free phosphate buffered saline (PBS) containing 0.15 mol/L NaCl, 
0.005% (w/v) EDTA-Na2, and 0.006% (w/v) NaN3 (pH 7.4). The isolated HDL 
were stored at 4oC for up to 7 weeks, until further analysis.  
2.4 Isolation of plasma depleted of apoB-containing lipoproteins by 
use of polyethylene glycol 
Plasma depleted of apoB-containing lipoproteins (but still containing HDL) 
was isolated by precipitating apoB-containing lipoproteins with polyethylene 
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glycol (PEG) 6000387. PEG-6000 was prepared at a concentration of 200 
mg/mL in distilled water. The PEG-6000 solution was added to an equal 
volume of plasma (1:1 v/v ratio of plasma: PEG), vortexed briefly and placed 
on ice for 20 minutes to allow for the formation of a white precipitate 
containing LDL and VLDL. Each sample was then spun at 15,000 rpm for 20 
minutes at 4oC in a microfuge to pellet the precipitate. The supernatant 
containing HDL and other plasma proteins was removed without disturbing 
the pellet and stored at 4oC until further analysis.  
2.5 Non-denaturing gradient gel electrophoresis  
The Stokes’ diameters of HDL isolated by sequential ultracentrifugation, as 
described in Section 2.3, were determined by electrophoresis on 4-30% non-
denaturing polyacrylamide gradient gels (Alamo, CBS scientific, San Diego, 
blue. High molecular weight protein standards (Amersham Pharmacia 
Biotech, Stockholm, Sweden) containing thyroglobulin (diameter 17.0 nm), 
ferritin (diameter 12.1 nm), lactase dehydrogenase (diameter 8.1 nm) and 
bovine serum albumin (BSA) (diameter 7.1 nm) were also loaded onto the 
gels, which were electrophoresed at 150 V for 20 hours. The running buffer 
contained 0.09 M Tris, 0.08 M boric acid and 0.003 M EDTA-Na2 (pH 8.4).   
Following electrophoresis, the gels were fixed for 1 hour with 10% (w/v) 
sulphosalicylic acid and stained for 3 hours with Coomassie Blue G-250 
(0.04% (w/v) in 5% (v/v) perchloric acid) and destained overnight with 5% 
(v/v) acetic acid. The gels were scanned using a Sharp JX 610 high-
resolution scanner (Osaka, Japan) and analysed using ImageQuantTL 
software (GE Life Sciences, Buckinghamshire, UK). Particle diameters were 
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determined by comparing the migration distance of the HDL with the 
diameters of the known protein standards.  
2.6 Two-dimensional gradient gel electrophoresis 
Agarose gels 0.6% (w/v) were prepared with 25 mL of buffer containing 10 
mM barbitone and 50 mM sodium barbitone (pH 8.6, ionic strength 0.05). 
The agarose solution (21 mL) was poured into an electrophoresis tray (10 x 7 
mm) and allowed to set for 30 minutes at room temperature, then stored at 
4oC until needed. Plasma samples (10 µL) were diluted 2:1 with a tracking 
dye (40% w/v sucrose and 0.01% w/v bromophenol blue) and loaded into the 
wells of the agarose gel and electrophoresed at 100 V for 60 minutes. 
Individual tracks were excised and annealed to 3-40% non-denaturing 
polyacrylamide gradient gels (CBS Scientific, CA, USA), which were 
electrophoresed at 150 V for 20 hours57. The proteins were then transferred 
electrophoretically to a polyvinylidene difluoride (PVDF) membrane (pore 
size: 2uM, Bio-Rad, CA, USA) using a Bio-Rad Trans-blot electrophoresis 
unit. Briefly, the PVDF membrane was immersed in 100% methanol for 1 
minute at room temperature, and then equilibrated in transfer buffer (25 mM 
Tris-base, 192 mM glycine and 20% (v/v) methanol, pH 8.3) for 10 minutes, 
along with two pieces of scotchbrite pads and two pieces of thick filter paper. 
These were then layered into a large transfer cassette in the following order; 
sponge (+ve), filter paper, PVDF membrane, two gels (side by side), filter 
paper, sponge (-ve). All components were kept immersed under transfer 
buffer as the layers were assembled and a 5-mL pipette tip was used to 
expel any air bubbles that were trapped inside the layers. The cassette was 
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then placed inside the Trans-blot electrophoresis unit. The transfer was 
carried out at 300 mA for 16 hours at 4oC. A maximum of 4 gels were 
transferred simultaneously in two large transfer cassettes.  After the transfer, 
the membranes were immunoblotted for human apoA-I, apoA-II, apoA-IV and 
apoE as described below.  
2.6.1 Immunoblotting for human apoA-I, apoA-IV and apoE 
PVDF membranes were incubated for 2 hours at room temperature with 
Blotto: 5% (w/v) non-fat dry milk containing Tris-buffered saline (10 mM Tris, 
150 mM NaCl and 0.1% Tween-20) (TBS-T) at room temperature to block 
interactions between non-specific proteins and the primary antibody. The 
membranes were then incubated at room temperature for 1 hour with the 
primary antibodies diluted in 1% (w/v) blotto. The goat anti-human apoA-I 
polyclonal antibody (Merck, Darmstadt, Hesse, Germany) was diluted 1:5000 
in 1% blotto. The goat anti-human apoA-IV (Santa Cruz Biotechnology, 
Dallas, Texas, USA) and apoE (Meridian Life Sciences, Memphis, TN, USA) 
antibodies were diluted 1:100 and 1:500 respectively. The membranes were 
then washed (3 x 5 minutes) in TBS-T to remove unbound primary 
antibodies, and incubated for 1 hour at room temperature with the secondary 
antibodies, anti-sheep IgG conjugated to horse radish peroxidase (HRP) 
(Abcam, Cambridge, MA, USA) diluted 1:10000 in 1% (w/v) Blotto for apoA-I 
and apoA-IV, or with anti-goat apoE HRP (Meridian Life Sciences, Memphis, 
TN, USA) diluted 1:1000. The membranes were then washed with TBS-T (3 
x 5 minutes), developed using ECL solution (GE Healthcare, Little Chalfont, 
Buckinghamshire, UK) and visualised using the ChemiDocTM XRS system 
(Bio-Rad, Hercules, California, USA).  
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Membranes that required re-blotting for better image quality were briefly 
washed (3x5 min) in TBS-T and incubated at 55 ºC for 30 minutes with a 
stripping buffer containing 0.5 M Tris, 1.6% (w/v) SDS and 0.00056% (v/v) β- 
mercaptoethanol.  
2.7 Size exclusion chromatography 
VLDL, LDL and HDL were resolved by loading plasma (100 µL) onto two 
Superdex Fast Flow columns (Superdex 200 10/300 GL) connected in series 
and attached to an AKTA Fast Performance Liquid Chromatography (FPLC) 
system (Amersham Pharmacia Biotech, Stockholm, Sweden). The columns 
were pre-equilibrated with endotoxin-free PBS. VLDL, LDL and HDL were 
eluted from the columns at a flow rate of 0.3 mL/minute and fractions (0.3 
mL) were collected388.  
2.8 CETP activity assay for the transfer of radiolabelled cholesteryl 
esters from HDL to LDL 
2.8.1 Isolation of LDL 
LDL (1.019 <ρ< 1.055 g/mL) were isolated from fresh human plasma by 
sequential ultracentrifugation386 using a Beckman 100.4 Ti rotor in a 
Beckman TL-100 bench-top ultracentrifuge maintained at 4°C (Beckman 
Instruments, Fullerton, CA, USA). Blood was collected in EDTA-Na2 tubes 
and spun at 3,000 rpm for 10 minutes to obtain plasma. The plasma was 
adjusted to a density of 1.019 g/mL with solid KBr and spun at 100,000 rpm 
for 16 hours at 4oC. The ρ>1.019 g/mL fraction was collected by tube slicing, 
adjusted to a density of 1.055 g/mL with solid KBr and spun again at 100,000 
rpm for 16 hours at 4oC. The ρ<1.055 g/mL fraction was collected by tube 
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slicing, dialysed for 2-3 hours against a 1.055 g/mL KBr density solution 
containing EDTA-Na2 (100 mg/L) and NaN3 (200 mg/L), then ultracentrifuged 
for a further 16 hours at 100,000 rpm. The ρ<1.055 g/mL fraction was 
isolated by tube slicing and dialysed against 10 mM Tris-buffered saline 
containing 150 mM NaCl, 0.006% (w/v) NaN3, and 0.005% (w/v) EDTA-Na2 
(pH 7.4). The apoB concentration was determined with an 
immunoturbidometric assay on a Hitachi 902 auto-analyser (Roche 
Diagnostics, Mannheim, Baden-Württemberg, Germany). 
2.8.2 Radioactive labelling of HDL cholesteryl esters 
Human blood was collected in EDTA-Na2 tubes and centrifuged at 3,000 rpm 
for 10 minutes to isolate plasma. The HDL fraction (ρ>1.13 g/mL) was 
isolated from plasma by ultracentrifugation. This procedure was carried out 
at 4oC using a Beckman 100.4 Ti rotor in a Beckman TL-100 benchtop 
ultracentrifuge (Beckman Instruments, Fullerton, CA, USA). The plasma was 
adjusted to a density of 1.13 g/mL with solid KBr and ultracentrifuged at 
100,000 rpm for 16 hours at 4oC. The ρ>1.13 g/mL fraction was collected by 
tube slicing and dialysed against 10 mM Tris-buffered saline containing 150 
mM NaCl, 0.006% (w/v) NaN3, and 0.005% (w/v) EDTA-Na2 (pH 7.4). 
[3H] unesterified cholesterol (100 µCi) in ethanol (50 µL), was placed in a 
scintillation vial and evaporated under N2. The dialysed ρ>1.13 g/mL fraction 
of plasma was added to the vial and the mixture was incubated at 37ºC for 
24 hours.  
The solution was then adjusted to a density of 1.13 g/mL with KBr and 
ultracentrifuged at 100,000 rpm for 16 hours. The ρ>1.13 g/mL fraction was 
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collected by tube slicing, adjusted to 1.21 g/mL with KBr and ultracentrifuged 
at 100,000 rpm for 16 hours. The ρ<1.21 g/mL fraction was collected by tube 
slicing and dialysed for 4 hours in a 1.21 g/mL density solution containing 
KBr with EDTA-Na2 (100 mg/L) and NaN3 (200 mg/L), and ultracentrifuged 
for a further 16 hours at 100,000 rpm. The ρ<1.21 g/mL fraction (HDL that 
contained radiolabelled cholesteryl esters [CE] in HDL3) was collected and 
dialysed against 10 mM Tris-buffered saline containing 150 mM NaCl, 
0.006% (w/v) NaN3, and 0.005% (w/v) EDTA-Na2 (pH 7.4). As judged by 
thin-layer chromatography, more than 95% of total HDL radioactivity was in 
the CE moiety389.   
2.8.3 CETP assay 
CETP activity was determined by measuring the ability of plasma samples to 
promote the transfer of radiolabeled CE from 3H-CE-HDL3 to unlabelled LDL 
as previously described390,391. The incubation contained 42 nmol of total 
cholesterol in LDL and 14 nmol of total cholesterol in the 3H-CE-HDL3. 3H-
CE-HDL3 (10 µL) and LDL-C (10 µL) were incubated for 3 hours at 37ºC in 
the presence of 50 µL of plasma and TBS (95 µL). The total volume of the 
incubation mixture was 175 µL. The reaction was stopped by placing the 
samples on ice for 10 minutes. Ice-cold BSA (5% w/v, 50 µL) was added, 
followed by heparin:MnCl2 (1:1, 25 µL) to precipitate the LDL. The tubes 
were vortexed, microfuged and placed on ice for 15 minutes. The 
supernatant (200 µL) was counted for 5 minutes in a liquid scintillation 
counter. CETP activity was calculated as the loss of radiolabelled CE from 
the HDL and was expressed as nmol CE transferred/mL of plasma/hour.  
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2.9  Determination of cell surface ICAM-1 and VCAM-1 expression 
2.9.1 Human coronary artery endothelial cell culture 
Human coronary artery endothelial cells (HCAECs; passage 2 to 4), (Cell 
Applications Inc., San Diego, CA, USA) were cultured in meso-endothelial 
cell growth medium (Cell Applications Inc., San Diego, CA, USA) and 
maintained at 37oC. Regular screening for mycoplasma was performed using 
MycoAlert test kit (Lonza, Basel, Switzerland) to ensure that the cells were 
mycoplasma-free.  
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2.9.2 HDL and TNF-α incubations 
HCAECs were seeded in 24-well plates at a density of 5 x 104 cells per well 
and incubated overnight at 37oC. Cells were then incubated for 16 hours at 
37oC with either PBS (negative control) or with HDL isolated from 
prednisone- and antibiotic-treated subjects (final HDL protein concentration 1 
mg/mL). The cells were then incubated at 37°C for 5 hours with TNF-α (0.2 
ng/mL), after which the medium was removed and the HCAECs were 
harvested for flow cytometry analysis (below).  
2.9.3 ICAM-1 and VCAM-1 cell surface expression by flow cytometry 
HCAECs were incubated at 4oC in foil for 30 minutes with an ICAM-1 
(CD54)-FITC conjugated antibody (200 µL/mL; Beckman-Coulter, Pasadena, 
CA, USA), and a VCAM-1 (CD106)-PeCy5 conjugated antibody (20 µL/mL; 
BD Pharmingen, East Rutherford, NJ, USA). Antibodies were diluted in PBS 
containing 10% heat-inactivated human serum (HIHS). The cells were 
washed (3 x 500 µL) with PBS, then incubated for 5 minutes at room 
temperature with 2 mM EDTA-Na2 (300 µL) in PBS. PBS containing 10% 
HIHS (700 µL) was added to each well and the contents were transferred to 
eppendorf tubes and cell pellets were obtained by centrifugation for 5 
minutes at 5,000 rpm. The cells were re-suspended in PBS containing 2% 
HIHS (500 µL). ICAM-1 and VCAM-1 expression was determined using a 
BioRad Flow Cytometer (FC500, Beckman Coulter, Pasadena, CA, USA) 
and Quantity-One 4.6.5 flow cytometry software (BioRad, Hercules, CA, 
USA). 
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2.9.4 Effect of prednisolone added in vitro on TNF-α induced ICAM-1 
and VCAM-1 expression 
HCAECs were seeded at a density of 5 x 104 cells-per-well in 24 well plates 
and incubated overnight at 37oC with meso-endothelial cell growth medium 
(Cell Applications). The cells were then incubated for 30 minutes at 37oC 
with either PBS (negative control) or the active metabolite of prednisone, 
prednisolone (final concentration 1, 2, 5 and 20 µg/mL); then further 
incubated for 5 hours with TNF-α (0.2 ng/mL). HCAECs were washed twice 
with cold PBS and ICAM-1 and VCAM-1 cell surface expression was 
determined as described in Section 2.9.3.  
2.10 Assays for plasma markers of inflammation 
The plasma concentrations of MCP-1, soluble ICAM-1 (sICAM-1) and soluble 
VCAM-1 (sVCAM-1) were determined by enzyme-linked immunosorbent 
assay (ELISA) (Quantikine, R&D Systems, MN, USA). Briefly, standards and 
plasma samples were pipetted into microplate wells containing monoclonal 
antibodies specific for MCP-1, sICAM-1 or sVCAM-1. The dilution and 
incubation parameters for each marker are presented in Sections 2.10.1-
2.10.2. Unbound proteins were removed using a Bio-Rad autowasher, and 
an enzyme-conjugated polyclonal antibody was added to the wells. Samples 
were incubated at room temperature. The wells were then washed before the 
addition of a substrate solution containing equal volumes of hydrogen 
peroxide and tetramethylbenzidine. The reaction was neutralised with 2N 
sulphuric acid, and the optical density of each well was determined by 
measuring absorbance at 450 nm using photospectroscopy. Plasma 
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concentrations of CRP were determined by laser nephelometry as described 
in Section 2.10.4.  
2.10.1 MCP-1 
Quantification of MCP-1 was as follows; 96-well polystyrene ELISA plates 
were layered with 50 µL/well of the assay diluent. Standards, samples or 
controls (200 µL, in duplicate) were added to each well and the plate was 
incubated for 2 hours at room temperature. The MCP-1 standard 
concentration range was from 0 to 1000 pg/mL. Plasma samples were used 
neat. The wells were washed with washing buffer (3 x 400 µL). The MCP-1 
polyclonal antibody (200 µL) was added to each well and incubated for an 
additional 2 hours at room temperature. The wells were then washed with 
washing buffer (3 x 400 µL) and the chromogenic substrate (200 µL) was 
added and incubated for 30 minutes at room temperature. MCP-1 levels 
were then measured as described above. 
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2.10.2 sICAM-1 and sVCAM-1 
Plasma levels of sICAM-1 and sVCAM-1 were determined using the 
procedure outlined in Section 2.10 with minor modifications: the initial 
incubation time was decreased to 1.5 hours at room temperature and the 
samples were diluted 1:10 for sICAM-1 and 1:20 for sVCAM-1. The sICAM-1 
standard concentration range was 0-50 ng/mL. The sVCAM-1 standard 
concentration range was 0-200 ng/mL.  
2.10.3 CRP 
Plasma CRP levels in COPD and control subjects on days 1 and 5 of 
treatment were determined by laser nephelometry (Roche, Mannheim, 
Germany)392. The high-sensitivity CRP (hs-CRP) assays were performed by 
the Pathology Department, Royal Prince Alfred Hospital, Sydney. 
2.11 Assays for plasma lipid, lipoprotein and apolipoprotein 
concentrations  
Plasma apoA-I, apoA-II and apoB concentrations were determined 
immunoturbidometrically on an AU480 auto-analyser (Beckman Coulter 
Diagnostics, Pasadena, CA, USA) using goat anti-human apoA-I393, goat 
anti-human apoA-II394 and goat anti-human apoB393 polyclonal antibodies 
(Calbiochem, CA, USA). Plasma total cholesterol395, triglyceride396 and 
phospholipid397 concentrations were determined by enzymatic microplate 
assays using Wako Chemicals kits (Osaka, Japan). Optical densities were 
measured spectrophotometrically using a microplate reader at 600 nm 
absorbance for triglycerides and phospholipids, and 505 nm absorbance for 
total cholesterol. 
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The protein content of HDL isolated by sequential ultracentrifugation was 
measured by bicinchoninic acid assay (BCA)398. A solution of bicinchoninic 
acid and Triton X-100 (1:100 v/v, Buffer A) was combined with a copper (II) 
sulphate pentahydrate solution (4% w/v, Buffer B) at a ratio of 50:1 (v/v). A 
standard curve (100-2000 µg/mL) was generated using dilutions of a 2 
mg/mL fatty acid-free BSA stock solution.   
HDL lipid composition was determined after precipitating of apoB-containing 
lipoproteins from plasma using PEG-6000, as described in Section 2.4. The 
concentrations of total cholesterol395, triglyceride396, phospholipid397 and 
unesterified cholesterol103 in the PEG-treated samples were determined  
enzymatically using a Beckman Coulter AU480 auto-analyser. CE 
concentrations were calculated as the difference between the concentration 
of total cholesterol and unesterified cholesterol. The concentrations of apoA-I 
and apoA-II in the PEG-6000 supernatant were determined 
immunoturbidometrically on a Beckman Coulter AU480 auto-analyser. Given 
that apoA-I and apoA-II account for approximately 90 percent of the total 
protein content of HDL, the HDL protein composition was estimated as the 
sum of apoA-I and apoA-II concentrations divided by 0.9. 
2.12 Statistical analysis 
All data are presented as mean ± SEM. Differences between groups were 
determined with a paired Student’s t-test or a Mann-Whitney non-parametric 
test. One-way ANOVA and the Newman-Keuls post hoc tests were used to 
compensate for multiple testing procedures. All analyses were performed 
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using GraphPad Prism Version 5.0 (San Diego, CA, USA). A two-tailed p 
value of <0.05 was considered to be significant. 
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EFFECTS OF PREDNISONE ON PLASMA LIPIDS AND LIPOPROTEINS 
3.1 INTRODUCTION 
Systemic inflammatory responses have the capacity to disrupt the 
metabolism of plasma lipids, as described in Section 1.7.4. This, in turn, can 
lead to changes in lipoprotein levels, as reported in a wide variety of 
inflammatory disorders319-321. Pulmonary inflammation, for example, is 
associated with decreased plasma lipid levels, particularly HDL-C399. There 
is currently no clear explanation for the decrease of plasma HDL-C levels 
during inflammation despite the inverse correlation of HDL-C with plasma 
SAA in patients with chronic inflammatory disease400.  
While prednisone and other related corticosteroids have been reported to 
markedly alter plasma lipid and lipoprotein levels as outlined in Section 1.8.3, 
the limited and conflicting results of studies involving acute and chronic 
administration of corticosteroids make it difficult to resolve the precise nature 
and extent of these changes. Chronic administration of corticosteroids has 
been associated with increases in plasma triglyceride and LDL-C levels and 
a decrease HDL-C levels19,22,381,382. When limiting the analysis to high-dose, 
acute administration of prednisone, the results of published studies 
document significantly elevated levels of plasma HDL-C21,330, however the 
effects on plasma apolipoproteins are limited and inconsistent18,21. The 
studies described in this chapter address the effects of short-term treatment 
with prednisone on plasma lipid and lipoprotein levels in COPD subjects. 
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3.2 METHODS 
3.2.1 Quantification of plasma HDL-C levels 
Plasma samples from COPD and lower respiratory tract infection subjects at 
days 1 and 5 of treatment, and 6 weeks post-treatment were depleted of 
apoB-containing lipoproteins as described in Section 2.4. Any cholesterol in 
these apoB-depleted samples is thus in the HDL fraction, the concentration 
of which was determined by an enzymatic assay technique described in 
Section 2.11. The HDL-containing, apoB-depleted samples used in these 
experiments were stored at 4°C for up to 1 day. They were not frozen.  
3.2.2 Quantification of plasma lipids and apolipoprotein 
concentrations  
Plasma was isolated by centrifugation as described in Section 2.2. Plasma 
apoA-I, apoA-II and apoB concentrations were determined 
immunoturbidometrically, while plasma total cholesterol, triglyceride and 
phospholipid concentrations were determined by enzymatic microplate 
assays. The details of these methods are outlined in Section 2.11.  
3.2.3 Statistical analysis 
The data obtained in this chapter are expressed as mean ± SEM. Students’ 
t-test for paired samples was used to determine whether differences between 
values were significant. Statistical significance was set at p<0.05.  
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3.3 RESULTS 
3.3.1 Clinical and demographic characteristics of study participants 
The clinical and demographic characteristics of the study participants are 
described in Table 3.1. The mean age of the prednisone-treated, COPD 
subjects was 65±2 years, while the antibiotic-treated lower respiratory tract 
infection subjects were an average of 54±3 years old. The majority of lower 
respiratory tract infection subjects were non-smokers (71%) while 50% of 
COPD subjects were former smokers. One subject from each group had a 
history of cardiovascular disease and one person in the prednisone group 
had diabetes. Patients with known history of lipid disorders or on lipid 
lowering drugs were excluded from the study. This included subjects with 
abnormally elevated levels of any or all lipids and/or lipoproteins 
(hypercholesterolemia, hyperlipidaemia and hypertriglyceridemia).  Normality 
was based on total cholesterol levels <5.2 mmol/L, triglyceride <2.0 mmol/L, 
1-2.5 mmol/L HDL-C and LDL-C <3.5 mmol/L.  
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Table 3.1 Demographic and clinical characteristics of study participants 
Demographic: Prednisone (n=16) Antibiotics (n=7)  
Male/ Female  8/8 3/4 
Age- years 65 ± 2 54 ± 3 
Medical history:    
Current smoker 44% 29% 
Former smoker 50% 0% 
Non-smoker 6% 71% 
Diabetes 1 0 
Hypercholesterolemia 0 0 
Hyperlipidaemia 0 0 
Hypertriglyceridemia 0 0 
Other dyslipidemic conditions 0 0 
Cardiovascular disease 1 1 
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3.3.2 Effect of prednisone treatment on plasma HDL-C levels 
After one day of prednisone treatment, plasma HDL-C levels were 1.4±0.2 
mmol/L and had increased to 1.7±0.1 mmol/L by day 5. Day 5 HDL-C levels 
were significantly greater than the mean HDL-C level of 1.1±0.1 mmol/L at 6 
weeks post-treatment (p<0.05) (Figure 3.1).  After one day of antibiotic 
treatment, the mean plasma HDL-C level in the lower respiratory tract 
infection subjects was 1.0±0.1 mmol/L. This was not significantly different 
from the mean HDL-C level at day 5 (0.9±0.1 mmol/L) or at week 6 post-
treatment (1.2±0.2 mmol/L) (Figure 3.1). 
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Figure 3.1 Plasma HDL-C levels 
HDL-C levels in the prednisone-treated COPD (black bars) and the antibiotic-
treated lower respiratory tract infection (grey bars) subjects at day 1 (D1) and 
day 5 (D5) of treatment, and at week 6 (W6) post-treatment (control). HDL 
was isolated as described in Section 2.4. The total cholesterol content of the 
isolated HDL samples was determined enzymatically, as described in 
Section 2.11. Results are presented as mean ± SEM.  
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3.3.3 Effect of prednisone on plasma lipid and apolipoprotein levels 
Plasma apoA-I, apoA-II, apoB, total cholesterol, phospholipid and triglyceride 
levels were measured in the prednisone-treated COPD and the antibiotic-
treated lower respiratory tract infection subjects as shown in Figures 3.2 A-F.  
Plasma apoA-I levels at day 1 (1.2±0.1 mg/mL) and day 5 (1.3±0.1 mg/mL) 
of prednisone treatment were significantly greater than at 6 weeks post-
treatment (1.1±0.1 mg/mL). Triglyceride levels at day 5 (1.2±0.1 mmol/L) of 
prednisone treatment were significantly lower than at 6-weeks post-treatment 
(1.5±0.2 mmol/L). Treatment with prednisone did not affect plasma apoA-II, 
apoB, total cholesterol or phospholipid levels. Treatment with antibiotics, by 
contrast, was associated with significantly decreased plasma apoA-I levels.  
On days 1 and 5 of antibiotic treatment, the mean apoA-I levels were 0.8±0.1 
mg/mL (p<0.005) and 0.9±0.0 mg/mL (p<0.05), respectively, compared to 
1.3±0.1 mg/mL at 6 weeks post-treatment. The antibiotic-treated subjects 
also had significantly lower plasma apoA-II levels on days 1 (0.5±0.0 mg/mL) 
and 5 (0.7±0.1 mg/mL) compared to 6 weeks post- treatment (0.9±0.1 
mg/mL). Antibiotic treatment did not change plasma apoB, total cholesterol, 
phospholipid or triglyceride levels when we compared days 1 and 5 of 
treatments to 6 weeks post-treatment.  
  
	   CHAPTER THREE 
 
 76 
A 
 
B 
 
C 
 
  
0.0
0.5
1.0
1.5
2.0
Prednisone
Non- steroidal** 
* 
D 1 D 5 W 6 D 1 D 5 W 6 
ap
oA
-I 
(m
g/
m
L)
  * 
* 
0.0
0.5
1.0
1.5
2.0
Prednisone
Non- steroidal
D 1 D 5 W 6 D 1 D 5 W 6 
ap
oA
-II
 (m
g/
m
L)
  
* 
* 
0.0
0.5
1.0
1.5
2.0
Prednisone
Non- steroidal
D 1 D 5 W 6 D 1 D 5 W 6 
ap
oB
 (m
g/
m
L)
  
	   CHAPTER THREE 
 
 77 
D 
 
E 
 
F 
 
  
0
1
2
3
4
5
6
Prednisone
Non- steroidal
D 1 D 5 W 6 D 1 D 5 W 6 
To
ta
l C
ho
le
st
er
ol
 (m
m
ol
/L
)  
0
1
2
3
4
Prednisone
Non- steroidal
D 1 D 5 W 6 D 1 D 5 W 6 
Ph
os
ph
ol
ip
id
 (m
m
ol
/L
)  
0.0
0.5
1.0
1.5
2.0
Prednisone
Non- steroidal
D 1 D 5 W 6 D 1 D 5 W 6 
Tr
ig
ly
ce
rid
e 
(m
m
ol
/L
)  
* 
	   CHAPTER THREE 
 
 78 
Figure 3.2 (A-F) Plasma lipid and apolipoprotein levels 
Plasma lipid and apolipoprotein levels in prednisone-treated COPD subjects 
(black bars) and antibiotic-treated lower respiratory tract infection subjects 
(grey bars). Results are shown for day 1 (D1), day 5 (D5) of treatment, and 
at week 6 (W6) post-treatment (control). Plasma apoA-I (panel A), apoA-II 
(panel B) and apoB (panel C) levels were determined 
immunoturbidometrically as described in Section 2.11. Plasma total 
cholesterol (panel D), phospholipid (panel E) and triglyceride (panel F) levels 
were determined with enzymatic microplate assays as described in Section 
2.11. Results are presented as mean ± SEM.  
*p<0.05, **p<0.005  
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3.4 DISCUSSION 
In this study, the samples collected 6 weeks after treatment have been taken 
as no-treatment controls and used as control values against which the values 
at days 1 and 5 of treatment are compared. The half-life of prednisone and 
prednisolone in humans is between 2.5-3.5 hours346 (Section 1.8.2), making 
the active metabolite biologically unavailable within the circulation at 6 weeks 
post-treatment. This study establishes that treatment of COPD subjects with 
prednisone increases plasma HDL-C and apoA-I levels and decreases 
triglyceride levels but does not change circulating concentrations of apoA-II, 
apoB, total cholesterol or phospholipids.  
The effects of prednisone on the COPD subjects in this study are consistent 
with previous reports, where acute corticosteroid administration significantly 
increased HDL-C and apoA-I levels18,20,21,401,402. There are limited reports on 
the effects of prednisone on plasma triglyceride levels in the literature and 
there is currently no clear explanation for the prednisone-induced decrease 
in triglyceride levels observed in COPD subjects. The reduction in plasma 
triglyceride levels may reflect an increased activity of lipoprotein lipase or 
possibly enhanced clearance of triglyceride-rich lipoproteins403.  
The underlying mechanism of the prednisone-induced increase in plasma 
apoA-I levels has previously been attributed to the induction of hepatic apoA-
I gene transcription404-407. The mechanism for the increase in HDL-C level 
during corticosteroid treatment, on the other hand, has not been clarified. 
Several mechanisms may be responsible for this observation; decreased 
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activity of hepatic triglyceride lipase408, corticosteroid-stimulated liver 
production of nascent HDL409 or a decrease in CETP activity410,411.  
Results from human and animal studies suggest that both HDL synthesis 
and clearance may be affected by corticosteroids412,413. Data from 
pharmacological and clinical studies reveal an inverse correlation between 
hepatic lipase activity and the plasma HDL-C levels in humans414,415. In vivo 
studies have shown that corticotrophin treatment decrease hepatic lipase 
activity, which can increase apoA-I synthesis and thereby increase plasma 
HDL-C levels409. The increase in HDL levels may also be attributed to a 
corticosteroid-induced decrease in HDL catabolism. For instance, hepatic 
triglyceride lipase is involved in the uptake of HDL by the liver199,200. It has 
been shown that hepatic triglyceride lipase activity is decreased in rats 
following administration of the corticosteroid-producing hormone 
corticotrophin. This is associated with reduced hepatic uptake of HDL413. 
Therefore, the increase in plasma HDL-C and apoA-I levels in the 
prednisone-treated subjects in this study may be attributed to both the 
increased production and decreased catabolism of HDL particles. The 
clinical significance of an increase in HDL-C is the associated decrease in 
cardiovascular risk416. However, there is no evidence that short-term 
intervention with prednisone will have a long lasting impact on CVD risk in 
these individuals.  
Contrary to the effects of prednisone, antibiotic treatment does not promote 
the increase in plasma HDL-C or apoA-I levels. However, antibiotic-treated 
lower respiratory tract infection subjects show a significant decrease in 
plasma apoA-I and apoA-II levels with respect to 6 week post-treatment 
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levels. Previous studies have shown that apoA-I can bind to antibiotics (such 
as doxorubicin), which increase its cellular uptake by SRB1 in the liver417, 
which might explain these results.  
The proceeding chapter describes the changes in HDL size, composition and 
apolipoprotein distribution during prednisone therapy.  
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EFFECTS OF PREDNISONE ON THE SIZE, COMPOSITION AND SUB- 
POPULATION DISTRIBUTION OF HDL  
4.1 INTRODUCTION 
This chapter aims to characterise the prednisone-induced changes to HDL 
size, composition and the distribution of apoA-I-, apoA-IV- and apoE-
containing HDL particles.  
Changes in HDL size and composition before, during and after an 
inflammatory response, have the capacity to identify the HDL sub-
populations that are important for the regulation of inflammation. Several 
studies have reported variations in the lipid and apolipoprotein composition 
of plasma lipoproteins during acute phase responses323,418,419.  
Studies in rodents and primates have suggested that acute inflammation 
alters the composition of HDL420,421, increases HDL catabolism329, enriches 
HDL with SAA, an acute phase protein that is bound mostly to HDL3 in the 
circulation326,422, and concomitantly reduces the amount of apoA-I associated 
with HDL423. Studies in humans have shown marked differences in the lipid 
composition of normal and acute phase HDL. Inflammation-induced 
remodelling of HDL results in the displacement of apoA-I by SAA, the 
replacement of cholesteryl esters with triacylglycerol and a decrease in the 
amount of small and medium sized HDL particles424,425. 
Intervention of pulmonary inflammation with prednisone is now well-
documented to increase circulating HDL-C levels330. However, the 
mechanisms by which prednisone affect HDL particle size, composition and 
distribution have not yet been determined. The results of Chapter 3 show 
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that treatment with prednisone increases plasma HDL-C and apoA-I levels, 
and reduces plasma triglyceride, which is a common clinical outcome of 
CETP inhibition426.  
CETP regulates the distribution of cholesteryl esters and triglycerides 
between plasma lipoproteins427,428. Genetic deficiency of CETP is associated 
with markedly elevated HDL-C levels191,429. More specifically, individuals that 
have no measurable CETP mass or activity in their plasma have a 3-to 4-fold 
increase in HDL lipids (cholesterol and phospholipid) and a 1.7-fold increase 
in plasma apoA-I levels191. CETP gene mutations, which result in partial 
CETP deficiency, cause a 1- to 2-fold elevation in HDL-C levels430. In 
subjects homozygous for CETP deficiency, HDL size and cholesteryl ester 
levels are increased and, in addition to containing apoA-I and apoA-II, the 
particles are enriched in apoE and apoC-II192. The increased HDL 
concentration in CETP-deficient subjects has been attributed to a reduction 
in the rate of apoA-I and apoA-II catabolism, with the rate of synthesis of 
both apolipoproteins remaining unaffected431.  
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4.2 METHODS 
4.2.1 HDL compositional analysis  
The composition of the HDL from prednisone- and antibiotic-treated subjects 
was determined using plasma depleted of apoB-containing lipoproteins as 
described in Section 2.4. The lipid (phospholipid, unesterified cholesterol, 
cholesteryl ester and triglyceride) and apolipoprotein concentrations of these 
samples, which contain HDL as the only lipoprotein, were determined using 
the immunoturbidometric and enzymatic assays described in Section 2.11.  
4.2.2 Gel permeation chromatography  
VLDL, LDL and HDL were resolved by subjecting plasma samples to size 
exclusion chromatography as outlined in Section 2.7. The apoA-I and apoB 
concentrations of each fraction were determined immunoturbidometrically, 
while total cholesterol and triglyceride concentrations were determined 
enzymatically as described in Section 2.11.  
4.2.3 Non-denaturing gradient gel electrophoresis of isolated HDL  
HDL were isolated by sequential ultracentrifugation as described in Section 
2.3. The isolated HDL samples were subjected to electrophoresis on 4-30% 
non-denaturing polyacrylamide gradient gels. The Stokes’ diameters of the 
samples were determined with ImageQuantTL software as described in 
Section 2.5.  
4.2.4 HDL apolipoprotein distribution  
The distribution of apoA-I, apoA-IV and apoE in the HDL from the 
prednisone-treated subjects was determined by two-dimensional gel 
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electrophoresis as described in Sections 2.6-2.6.1.  
4.2.5 CETP activity 
The activity of CETP was determined by measuring the ability of plasma to 
promote the transfer of radiolabelled cholesteryl esters from HDL3 to 
unlabelled LDL as described in Sections 2.8.1-2.8.3.  
4.2.6 Statistical analysis  
The data obtained in this chapter are expressed as mean ± SEM. Students’ 
t-test for paired samples was used to determine whether differences between 
values were significant. Statistical significance was set at p<0.05.  
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4.3 RESULTS 
4.3.1 Effect of prednisone treatment on the concentration of HDL 
constituents in apoB-depleted plasma 
The composition of the HDL shown in Table 4.1 is presented as the molar 
ratio of each constituent relative to apoA-I. When compared to basal values 
at 6 weeks post-treatment, the molar ratio of total cholesterol/apoA-I was not 
significantly different on day 1 (28.8±3.5 vs 35.1±4.8), but increased to 
40.6±3.6 on day 5 of prednisone treatment (p<0.05). Treatment with 
prednisone did not affect the molar ratio of phospholipid/apoA-I or 
triglyceride/apoA-I. The molar ratios of total cholesterol/apoA-I, 
phospholipid/apoA-I and triglyceride/apoA-I did not change in the antibiotic-
treated, lower respiratory tract infection group. 
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Table 4.1 Ratios of HDL lipids to apoA-I (mole/mole) 
 
The molar ratio of each HDL constituent relative to apoA-I from prednisone-
treated COPD subjects (n=4) and antibiotic-treated lower respiratory tract 
infection subjects (n=4) at day 1 and day 5 of treatment and at week 6 post-
treatment. The concentrations of apoA-I, cholesterol, phospholipid and 
triglyceride were determined as described in Section 2.11. The values 
represent the mean ± SEM. Significance is determined for the samples 
obtained at week 6 relative to day 1 and day 5. *p<0.05  
HDL Constituent  Subjects Day 1 Day 5 Week 6 
  mol/mol A-I mol/mol A-I mol/mol A-I 
Total Cholesterol  Prednisone 35.1±4.8 40.6±3.6* 28.8±3.5 
Antibiotic 36.3±4.9 32.1±1.1 39.5±3.7 
Phospholipid  Prednisone 38.2±5.1 35.5±2.8 34.7±2.8 
Antibiotic 37.1±2.3 32.1±1.1 39.5±3.7 
Triglyceride  Prednisone 4.1±0.6 4.8±1.4 4.8±0.6 
Antibiotic 5.7±0.9 5.7±0.8 5.4±0.5 
	   CHAPTER FOUR 
 
 89 
4.3.2 Effect of prednisone treatment on HDL size and composition as 
judged by gel permeation chromatography  
Plasma samples collected from subjects after 1 (Figure 4.1., open symbols) 
and 5 (Figure 4.1., closed symbols) days of treatment with prednisone or 
antibiotics and at 6 weeks (Figure 4.1., crosses) post-treatment were 
subjected to gel permeation chromatography. Each panel represents a single 
subject. Prednisone-treated subjects are shown in Panels A-C, and the 
antibiotic-treated subjects are shown in Panels D-F. Irrespective of whether 
the subjects were treated with prednisone or antibiotics, all of the apoA-I was 
confined to the HDL fraction. Treatment with prednisone for 1 and 5 days 
increased plasma apoA-I levels and HDL size, as evidenced by the reduced 
elution time for apoA-I relative to the 6-week sample (Figure 4.1, Panels A-
C). Antibiotic treatment of the lower respiratory tract infection subjects, by 
contrast, decreased apoA-I levels on HDL particles at day 1 and day 5 of 
treatment but had no effect on HDL size (Figure 4.1, Panels D-F).  
In the prednisone-treated subjects, the apoB concentration in the LDL and 
VLDL fractions (Figure 4.2, Panels A-C) did not change over the treatment 
period. However, in some antibiotic treatment subjects, the apoB 
concentration in the LDL and VLDL fractions decreased at 1 and 5 days of 
treatment, relative to week-6 post-treatment (Figure 4.2, Panels D-F).   
HDL total cholesterol levels and particle size were increased in the COPD 
subjects after 1 and 5 days of treatment with prednisone relative to 6 weeks 
post-treatment (Figure 4.3, Panels A-C). The HDL and LDL total cholesterol 
concentration either decreased  (Figure 4.3, Panel D) or was not altered by 
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treatment with antibiotics in the lower respiratory tract infection subjects 
(Figure 4.3, Panels E and F).  
Most of the triglyceride was confined to the VLDL fraction. The triglyceride 
concentration in VLDL decreased on days 1 and 5 of prednisone treatment 
compared to what was observed at week 6 post-treatment (Figure 4.4, 
Panels A-C). Antibiotic treatment of the lower respiratory tract infection 
subjects did not affect the triglyceride concentration in VLDL (Figure 4, 
Panels D-F).  
  
	   CHAPTER FOUR 
 
 91 
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Figure 4.1 ApoA-I elution profiles for COPD subjects treated with 
prednisone and lower respiratory tract infection subjects treated with 
antibiotics 
The concentration of apoA-I in HDL, LDL and VLDL from three different 
subjects after 1 (open symbols) and 5 (closed symbols) days of treatment 
with prednisone (Panels A-C) or antibiotics (Panels D-F), and at 6 weeks 
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(crosses) post-treatment. Plasma samples were applied to two Superdex gel 
permeation chromatography columns connected in series as described in 
Section 2.7. The concentration of apoA-I in each fraction was determined 
immunoturbidometrically.  
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Figure 4.2 ApoB elution profiles for COPD subjects treated with 
prednisone and lower respiratory tract infection subjects treated with 
antibiotics 
The concentration of apoB in HDL, LDL and VLDL from three different 
subjects after 1 (open symbols) and 5 (closed symbols) days of treatment 
with prednisone (Panels A-C) or antibiotics (Panels D-F), and at 6 weeks 
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(crosses) post-treatment were applied to two Superdex gel permeation 
chromatography columns connected in series as described in Section 2.7. 
The concentration of apoB in each fraction was determined 
immunoturbidometrically.   
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Figure 4.3 Total cholesterol elution profiles for COPD subjects 
treated with prednisone and lower respiratory tract infection subjects 
treated with antibiotics 
The concentration of total cholesterol in HDL, LDL and VLDL from three 
different subjects after 1 (open symbols) and 5 (closed symbols) days of 
treatment with prednisone (Panels A-C) or antibiotics (Panels D-F), and at 6 
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weeks (crosses) post-treatment were applied to two Superdex gel 
permeation chromatography columns connected in series as described in 
Section 2.7. The total cholesterol concentration of each fraction was 
determined enzymatically.  
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Figure 4.4 Triglyceride elution profiles for COPD subjects treated with 
prednisone and lower respiratory tract infection subjects treated with 
antibiotics 
The concentration of triglyceride in HDL, LDL and VLDL from three different 
subjects after 1 (open symbols) and 5 (closed symbols) days of treatment 
with prednisone (Panels A-C) or antibiotics (Panels D-F), and at 6 weeks 
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(crosses) post-treatment were applied to two Superdex gel permeation 
chromatography columns connected in series as described in Section 2.7. 
The triglyceride concentration of each fraction was determined enzymatically.  
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4.3.3 Effect of prednisone treatment on HDL sub-population 
distribution  
HDL were isolated from plasma by sequential ultracentrifugation and the 
sub-population distribution of the isolated HDL was determined by 
electrophoresis on non-denaturing polyacrylamide gels. Each gel represents 
the distribution of HDL isolated from a single subject at day 1, day 5 and 
week 6. Figure 4.5 (Panels A-E, 5 different subjects) represent prednisone-
treated subjects while Figure 4.6 (Panels A-D, 4 different subjects) represent 
antibiotic-treated subjects.  
In the COPD subject (Figure 4.5, Panel A), the HDL profile at day 1 of 
prednisone treatment consisted of a single population with a Stokes’ 
diameter of 12.7 nm. By day 5 two sub-populations were apparent with 
diameters of 12.7 nm and 8.5 nm. At 6 weeks post-prednisone treatment the 
HDL consisted of two populations of smaller particles, 10.0 nm and 8.4 nm in 
diameter. For the COPD subject in Panel B, two major HDL populations with 
diameters 9.9 nm and 8.1 nm were apparent on day 1 of prednisone 
treatment. By day 5 of treatment both populations had increased slightly in 
diameter to 10.0 nm and 8.3 nm. At week 6 post-treatment there was only a 
single population of HDL particles with a diameter of 8.3 nm.  Similarly, on 
day 1 of prednisone treatment, the HDL from the subject in Panel C had two 
major populations of HDL 10.0 nm and 8.4 nm in diameter. At day 5 of 
treatment only a single population of particles 9.9 nm in diameter was 
present. At 6 weeks post-treatment the HDL were 8.5 nm in diameter. The 
COPD subject represented in Panel D had two major sub-populations of HDL 
10.1 nm and 8.3 nm in diameter at day 1 of prednisone treatment. At day 5 
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the populations of particles were 9.9 nm and 8.5 nm in diameter. Only a 
single population of small particles 8.6 nm in diameter was evident at week 6 
post-treatment. The HDL in the subject in Panel E consisted of multiple sub-
populations of particles with a mean diameter of 9.5 nm in diameter at day 1 
of prednisone treatment. By day 5 of prednisone therapy two populations of 
HDL with diameters of 9.8 nm and 8.7 nm were evident. At week 6 post-
treatment the HDL were 8.9 nm in diameter.  
Taken together, the results show that there is a consistent increase in HDL 
diameter at 1 and 5 days of prednisone treatment, relative to week-6 post-
treatment HDL samples.  
For the antibiotic-treated subject in Figure 4.6, Panel A there was a single 
population of HDL particles 8.8 nm in diameter on day 1 and 8.5 nm in 
diameter on day 5. At 6 weeks post-treatment, two populations of particles 
with diameters of 10.1 nm and 8.4 nm were apparent.  The results in Panel B 
show one predominant population of HDL particles 8.5 nm in diameter at day 
1 of treatment and 8.6 nm in diameter on day 5. At 6 weeks post-treatment 
the HDL were 8.8 nm in diameter. In Panel C most of the HDL particles were 
8.4 nm in diameter on day 1 and day 5 and two populations of particles 9.9 
nm and 8.2 nm in diameter were present at 6 weeks post-treatment. In Panel 
D the HDL were 9.3 nm in diameter on day 1 and day 5 of treatment. At 6 
weeks post-treatment the HDL in this subject consisted of a major population 
of particles 12.4 nm in diameter, with a second population of particles 8.8 nm 
in diameter, appearing as a broad shoulder on the descending arm of the 
main peak.  
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These results show that in some but not all antibiotic-treated subjects there is 
a decrease in HDL diameter at day 1 and 5 of treatment relative to week 6 
samples 
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Figure 4.5 Effect of treatment with prednisone on the sub-population 
distribution of HDL in subjects with COPD  
HDL (1.063 < ρ < 1.21 g/mL) were isolated by sequential ultracentrifugation 
(Section 2.3) from plasma samples collected at day 1, day 5 of COPD 
treatment and at 6 weeks post-treatment, and subjected to non-denaturing 
polyacrylamide gradient gel electrophoresis. Each gel represents the 
distribution of HDL isolated from a single subject. The gels were stained with 
Coomassie Blue, and scanned with a laser densitometer. The sub-population 
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distribution was determined by reference to high molecular weight standards 
of known diameter (Section 2.5). 
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D 
     
 
Figure 4.6 Effect of treatment with antibiotics on the sub-population 
distribution of HDL in subjects with lower respiratory tract infections 
HDL (1.063 < ρ < 1.21 g/mL) were isolated by sequential ultracentrifugation 
(Section 2.3) from plasma samples collected at day 1, day 5 of antibiotic 
treatment and at 6 weeks post-treatment for each lower respiratory tract 
infection subject and subjected to non-denaturing polyacrylamide gradient 
gel electrophoresis. Each gel represents the distribution of HDL isolated from 
a single subject at day 1, day 5 and week 6. The gels were stained with 
Coomassie Blue, and scanned with a laser densitometer. The sub-population 
distribution was determined by reference to high molecular weight standards 
of known diameter (Section 2.5). 
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4.3.4 Effect of prednisone treatment on HDL apolipoprotein 
distribution 
The sub-population distribution of HDL apolipoproteins in subjects treated 
with prednisone was determined by two-dimensional gel electrophoresis 
(Figures 4.7-4.9).  
4.3.4.1 Distribution of apoA-I 
After day 1 of prednisone treatment, the apoA-I in the HDL from the subject 
in Figure 4.7, Panel A, consisted of a single population of particles that 
migrated to a pre-β position and two α-migrating populations of particles. At 
day 5, the pre-β-migrating apoA-I had disappeared. At 6 weeks post-
treatment, the apoA-I was distributed among three α-migrating sub-
populations.  
For the subject in Panel B, the apoA-I was distributed among four α-
migrating populations of particles and a pre-β-migrating population of 
particles at day 1 of prednisone treatment. At day 5, the three smallest α-
migrating apoA-I populations had disappeared, leaving most of the apoA-I in 
large α-migrating particles and two populations of pre-β-migrating particles, 
one large and one small. At 6 weeks post-treatment, the apoA-I was 
distributed among four populations of α-migrating particles and a single 
population of pre-β-migrating particles.  
At day 1 of prednisone treatment the apoA-I in Panel C was distributed 
among three pre-β-migrating populations, together with two large and one 
small population of α-migrating particles. By day 5, the α-migrating particles 
had redistributed into two larger and two smaller α-migrating populations of 
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particles. Three pre-β-migrating particles were also present at day 5. By 6 
weeks post-treatment most of the apoA-I was distributed among four α-
migrating sub-populations, while the remainder of the apoA-I migrated to a 
pre-β position.  
Prednisone treatment in COPD subjects induced the redistribution to apoA-I 
on HDL to induce the increase in large apoA-I containing particles and the 
appearance of small pre-β-migrating-HDL.  
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Figure 4.7 Effect of treatment with prednisone on the distribution of 
apoA-I-containing HDL particles in subjects with COPD 
The distribution of apoA-I containing HDL sub-populations from 
representative COPD subjects at days 1 and 5 of prednisone treatment and 
at 6-weeks post-treatment was determined by two-dimensional gel 
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electrophoresis and immunoblotting for apoA-I (Section 2.6.1). Each panel 
represents the apoA-I distribution of a single subject. 
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4.3.4.2 Distribution of apoA-IV 
At days 1 and 5 of prednisone treatment, the apoA-IV-containing HDL were 
distributed among four α-migrating particles, in the subject in Figure 4.8, 
Panel A. By 6 weeks post-treatment, the largest population of apoA-IV-
containing particles had disappeared. The small pre-α-migrating particles 
seen in all three images are likely to be lipid-free apoA-IV that had 
dissociated from the HDL particles.  
The apoA-IV in Panel B was associated with one large and one smaller 
population of α-migrating particles at day 1 of prednisone treatment. By day 
5, two larger, α-migrating apoA-IV populations appeared, forming a total of 
three large apoA-IV populations. By 6 weeks post-treatment, the large, α-
migrating apoA-IV particles had disappeared leaving one small α-migrating 
population. Once again, smaller, pre-α-migrating lipid-free apoA-IV was seen 
in all three images as pre-α-migrating particles.  
On day 1 of prednisone treatment, the apoA-IV in the subject in Panel C was 
distributed among two large, α-migrating sub-populations of particles. By day 
5, all of the apoA-IV was incorporated into a single, large α-migrating 
population of particles. By 6 weeks post-treatment, the large α-migrating, 
apoA-IV-containing HDL were no longer apparent, with most of the apoA-IV 
having redistributed into a smaller α-migrating sub-population or into lipid-
free apoA-IV with pre-α mobility.  
These results suggest that prednisone treatment in COPD subjects induced 
an increase in large apoA-IV-containing particles. 
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Figure 4.8 Effect of treatment with prednisone on the distribution of 
apoA-IV-containing HDL particles in subjects with COPD 
The distribution of apoA-IV-containing HDL sub-populations in representative 
samples from COPD subjects at days 1 and 5 of prednisone treatment and at 
6 weeks post-treatment was determined by two-dimensional gel 
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electrophoresis and immunoblotting for apoA-IV (Section 2.6.1). Each panel 
represents the apoA-IV distribution of a single subject.  
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4.3.4.3 Distribution of apoE 
On day 1 and day 5  of prednisone treatement, the apoE-containing HDL in 
Figure 4.9, Panel A were distributed among several γ-migrating particles, 
one of which was very large. Smaller particles that migrated to a pre-β 
position were also apparent. By 6 weeks post-treatment, the very large 
apoE-containing HDL particles had disappeared leaving several smaller γ-
migrating and pre-β-migrating sub-populations of particles.  
For the subject represented in Panel B, apoE was distributed among one 
very large and several smaller γ-migrating population of particles on day 1. 
Some of the smaller particles had migrated to a pre-β position on day 5. By 6 
weeks post-treatment all of apoE was incorporated into smaller γ-migrating 
particles.  
On day 1 of prednisone treatment the apoE in Panel C was distributed 
among several large, γ-migrating sub-populations of particles. By day 5, only 
very large and smaller γ-migrating and pre-β-migrating apoE-containing HDL 
populations were apparent. By 6 weeks post-treatment, most of the apoA-IV 
was associated with large, γ-migrating sub-populations of particles. 
Taken together these results suggest that prednisone treatment in COPD 
subjects induced an increase in large apoE-containing particles. 
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Figure 4.9 Effect of treatment with prednisone on the distribution of 
apoA-E-containing HDL particles in subjects with COPD 
The distribution of apoE containing HDL sub-populations in representative 
samples from COPD subjects at days 1 and 5 of prednisone treatment and at 
6-weeks post-treatment was determined by two-dimensional gel 
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electrophoresis and immunoblotting for apoE (Section 2.6.1). Each panel 
represents the apoE distribution of a single subject.  
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4.3.5 Effect of prednisone treatment on CETP activity  
The preceding results show that treatment with prednisone increases the 
concentrations of HDL-C and apoA-I, and HDL particle size. These changes 
are reminiscent of what has been reported in people treated with CETP 
inhibitors. Therefore, additional studies looking at plasma CETP activity were 
performed to determine if prednisone treatment inhibits the activity of CETP.  
The mean plasma CETP activity in the prednisone-treated subjects at days 1 
and 5 was 30±6.2 and 43±5.3 nmol CE transferred/mL plasma/h, 
respectively, compared to 59±7.0 nmol CE transferred/mL plasma/h at 6 
weeks post-treatment (p<0.005 for both) (Figure 4.10).  
CETP activity was, by contrast, significantly increased in the antibiotic-
treated subjects on day 1 (71±4.4 nmol CE transferred/mL plasma/h) of 
treatment when compared to 6 weeks post-treatment (51±2.9 nmol CE 
transferred/ml plasma/h, p<0.0005). Plasma CETP activity on day 5 of 
antibiotic treatment (59±4.0 nmol CE transferred/mL plasma/h) was 
significantly higher than the activity at week 6 post-treatment (p<0.05) 
(Figure 4.11).  
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Figure 4.10 Plasma CETP activity in prednisone-treated subjects  
Plasma CETP activity in prednisone-treated subjects on days 1 and 5 of 
treatment, and at 6-weeks post-treatment. Plasma CETP activity was 
quantified as the transfer of radiolabelled cholesteryl esters from 3CE-HDL3 
to unlabelled LDL (Section 2.8.3). Each data point is representative of the 
CETP activity of a single subject. The horizontal lines represent the mean ± 
SEM on days 1 and 5 of treatment and at 6 weeks post-treatment. 
**p<0.005  
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Figure 4.11 Plasma CETP activity in antibiotic-treated subjects  
Plasma CETP activity in antibiotic-treated subjects on days 1 and 5 of 
treatment, and at 6-weeks post-treatment. Plasma CETP activity was 
quantified as the transfer of radiolabelled cholesteryl esters from 3CE-HDL3 
to unlabelled LDL (Section 2.8.3). Each data point is representative of the 
CETP activity of a single subject. The horizontal lines represent the mean ± 
SEM on days 1 and 5 of treatment and at 6 weeks post-treatment.  
*p<0.05, ***p<0.0005 
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4.4 DISCUSSION 
The results in this chapter establish that treatment with prednisone alters the 
size, composition and sub-population distribution of HDL. Prednisone 
treatment was associated with an increase in HDL-C and apoA-I 
concentrations, as well as HDL particle size. The results indicate that the 
increase in HDL size in these subjects may reflect an increase in large A-I-, 
apoA-IV- and apoE-containing HDL particles. The observed changes in HDL 
particle size and the increases in apoA-I and HDL cholesterol concentration 
were also associated with a concomitant reduction in CETP activity. 
Antibiotic treatment was associated with decreases in HDL apoA-I levels, 
HDL cholesterol concentration and a decrease in HDL size in some but not 
all subjects. These results were associated with an increase in CETP activity.   
When the results in this chapter are considered in light of the results in 
Sections 4.3.1 and 4.3.4, it follows that the increase in HDL size is most 
likely due to the combined effects of an increase in the protein and 
cholesterol content of the particles. As apoA-I-containing HDL can 
accommodate only a limited amount of cholesteryl esters, it follows that the 
large HDL in the prednisone-treated subjects must have acquired additional 
apolipoproteins, such as apoE. This is consistent with the size and 
cholesteryl ester content of the apoE-containing HDL being significantly 
greater than that of apoA-I-containing HDL432. It is also consistent with apoE 
being readily available in the interstitial fluid, via secretion from various cell 
types including hepatocytes, astrocytes, smooth muscle cells and 
macrophages, for incorporation into the HDL fraction432. ApoE has also been 
reported to associate with HDL when the particles are acted on by 
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LCAT433,434. When excess apoE is added to HDL in the presence of LCAT, 
cholesteryl esters are generated in the HDL and their diameter doubles in 
size434.  
The question that arises from this analogy is why there would be an increase 
in apoE-containing HDL particles, and what purpose would it serve in COPD 
patients. A possible explanation may relate to the functional properties of 
apoE which have been widely studied in the context of atherosclerosis435, 
Alzheimer’s disease436 and multiple sclerosis437.  Within these disease states 
apoE functions within the immune system to modulate inflammation and 
oxidation438 by suppressing neutrophil activation439, T cell proliferation440 and 
macrophage activation441-444. Therefore, the increase in apoE-containing 
HDL may be a physiological response to inflammation in COPD subjects.  
Part of the anti-inflammatory effects of prednisone may also be attributable to 
the acquisition of apoA-IV by HDL. There is substantial evidence that apoA-
IV has anti-inflammatory properties. Exogenous administration of 
recombinant human apoA-IV decreases the expression of myeloperoxidase, 
and pro-inflammatory cytokines in a mouse model of acute colitis116.  Human 
apoA-IV also blocks the LPS-induced stimulation of monocytes117. 
Lymphocytes from the blood, liver, spleen and thymus of apoE-KO mice 
overexpressing apoA-IV have been reported to produce fewer pro-
inflammatory cytokines than the lymphocytes from apoE-KO mice117.  
The appearance of pre-β-migrating-HDL within the plasma of prednisone-
treated COPD subjects in this study is of interest. It is possibly due to 
increased hepatic or intestinal synthesis of apoA-I, or to the dissociation of 
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apoA-I from spherical, α-migrating HDL that are being remodelled by plasma 
factors. The increased formation of pre-β-migrating HDL during inflammation 
may be explained by the displacement of apoA-I from HDL by SAA445, with 
plasma SAA levels increasing up to 1000-fold in response to injury, infection 
and inflammation446.  During an inflammatory response, SAA may become 
the predominant HDL-associated apolipoprotein subsequent to the 
dissociation of pre-β-migrating apoA-I/phospholipid complexes from the 
particles447,448 in a process that is mediated by PLTP449. While it is 
reasonable to assume that the displacement of apoA-I from HDL during an 
inflammatory response is the explanation for the increase in small pre-β-
migrating HDL at day 1 of prednisone treatment, it does not explain the 
presence of both pre-β-migrating HDL and large α-migrating A-I HDL on day 
5 of prednisone treatment, at which time the subjects should be showing 
signs of an improvement in their lipid profile. Therefore, the most likely 
explanation for the presence of both pre-β1-HDL and large α-migrating A-I 
HDL at this time point is via a prednisone-induced increase in apoA-I 
synthesis404-407. This explanation also adheres to the results of Chapter 3, 
which show an increase in plasma apoA-I levels during prednisone 
treatment.  
The observed changes in HDL size and composition during prednisone 
treatment were also associated with a concomitant reduction in CETP 
activity. This is consistent with the results of several studies that have 
established that glucocorticoid treatment reduce CETP activity and 
subsequently increase the cholesteryl ester content of HDL, thereby 
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increasing the size of the particles411,450-452. Glucocorticoid replacement in 
hypopituitary patients has been shown to decrease the rate of plasma 
cholesterol esterification and the transfer of cholesteryl esters from HDL to 
LDL411. Furthermore, in heart transplant recipients treated with 
glucocorticoids, a significant reduction in CETP activity was associated with 
high HDL-C concentrations, an increase in the cholesteryl ester content of 
HDL and a corresponding decrease in IDL and LDL453.  
In Chapter 3, a decrease in plasma apoA-I levels was observed in patients 
treated with antibiotics; in this chapter there is also a decrease in apoA-I and 
cholesterol levels in HDL particles on days 1 and 5 of antibiotic treatment in 
some subjects. Antibiotics have been shown to modulate plasma cholesterol 
levels454,455. The concomitant increase in CETP activity with the decrease in 
cholesterol and apoA-I levels in HDL may be responsible for the decrease in 
HDL size during antibiotic treatment456,457.   
While it is evident that prednisone therapy can increase HDL-C levels, 
increase HDL size and modify the sub-population distribution of HDL via a 
mechanism that may be attributed to CETP inhibition, the next question that 
arises is whether the cardioprotective functions of HDL are conserved under 
these circumstances.  
 
 
 
  
 
 
 
 
 
CHAPTER FIVE 
 
 
EFFECT OF PREDNISONE ON THE 
ANTI-INFLAMMATORY 
PROPERTIES OF HDL   
  
	   CHAPTER FIVE 
 
 125 
EFFECT OF PREDNISONE ON THE ANTI-INFLAMMATORY 
PROPERTIES OF HDL 
 
5.1 INTRODUCTION 
This chapter seeks to determine whether the well-characterized anti-
inflammatory actions of native HDL are impaired, maintained or enhanced by 
prednisone therapy.  
The anti-inflammatory properties of HDL have mainly been studied in the 
context of atherosclerosis and include their ability to decrease the expression 
of adhesion molecules on the surface of endothelial cells and inhibit 
monocyte adhesion to the endothelium2,458. Specifically, it has been shown 
that HDL inhibit the cytokine-induced (both TNF-α and IL-1) expression of the 
cellular adhesion molecules ICAM-1, VCAM-1 and E-selectin on the surface 
of cultured endothelial cells228,459,460 and is observed with both native human 
HDL and reconstituted discoidal HDL, which contain apoA-I, 
phosphatidylcholine and unesterified cholesterol460. This inhibition is 
concentration dependent and occurs over the physiological range of HDL 
concentrations228.  
The molecular mechanisms by which HDL inhibit adhesion molecule 
expression have been discussed in Section 1.6.2 and are proposed to be 
mediated by apoA-I, apoA-II and HDL phospholipids458,460. The magnitude of 
inhibition has been found to vary with the phospholipid composition of 
HDL461, but is unaffected by variations in particle shape and size, or 
apolipoprotein, cholesteryl ester or triglyceride content460.  
In vivo HDL administration has also been reported to reduce endothelial 
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expression of VCAM-1, ICAM-1 and MCP-1 in New Zealand White rabbits, 
where insertion of a non-occlusive silastic collar around the carotid artery 
was used to induce acute vascular inflammation462.  
The anti-inflammatory potential of rHDL therapy in humans has clinical 
implications. Most notable are the effects of rHDL on atherosclerotic lesions. 
For example, the infusion of rHDL in patients with peripheral vascular 
disease (PVD) has revealed a significant reduction in monocyte activation 
and a marked decrease in the lipid content and VCAM-1 expression of 
existing atherosclerotic plaques463.  
The ex vivo approach described in this chapter was designed to investigate 
whether treatment of COPD subjects with prednisone enhances the ability of 
HDL to inhibit the cytokine-induced expression of ICAM-1 and VCAM-1 in 
endothelial cells growing in tissue culture.  
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5.2 METHODS  
5.2.1 Isolation of HDL from prednisone- and antibiotic-treated subjects 
HDL were isolated from patient plasma by sequential ultracentrifugation as 
described in Section 2.3. 
5.2.2 Characterisation of HDL from prednisone- and antibiotic-treated 
subjects  
HDL diameters were determined by non-denaturing gradient gel 
electrophoresis as described in Section 2.5. The composition of isolated HDL 
was determined as described in Section 2.11.  
5.2.3 Effects of HDL isolated from prednisone- and antibiotic-treated 
subjects on ICAM-1 and VCAM-1 protein expression in TNF-α-
stimulated HCAECs 
HCAECs were seeded into 24-well plates at a density of 5 x 104 cells-per-
well (Section 2.9.1), incubated for 16 hours with either PBS (negative control) 
or with HDL isolated from prednisone- or antibiotic-treated subjects (final 
HDL protein concentration 1 mg/mL). The HDL protein concentration was 
measured using the BCA assay as described in Section 2.11. The HDL-
incubated HCAECs were then stimulated with TNF-α for an additional 5 
hours as described in Section 2.9.2. ICAM-1 and VCAM-1 expression was 
quantified by flow cytometry as described in Section 2.9.3.   
5.2.4 Effects of prednisolone on the expression of ICAM-1 and VCAM-1 
in TNF-α-stimulated HCAECs 
HCAECs were seeded at a density of 5 x 104 cells-per-well in meso-
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endothelial cell growth medium (Section 2.9.1) and incubated with either 
PBS (negative control) or with prednisolone (final concentration 1, 2, 5 and 
20 µg/mL) for 30 minutes. The incubation mixture consisting of HCAECs and 
prednisolone was then stimulated with TNF-α for an additional 5 hours 
(Section 2.9.4). ICAM-1 and VCAM-1 expression was quantified by flow 
cytometry as described in Section 2.9.3.   
5.2.5 Statistical analysis  
All data are expressed as mean ± SEM. Students’ t-test for paired samples 
was used to determine whether differences between values were significant. 
A value of p<0.05 was considered significant.  
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5.3 RESULTS 
5.3.1 Effect of pre-incubation with HDL isolated from prednisone-
treated subjects on ICAM-1 expression in TNF-α-stimulated HCAECs 
As reported previously, incubation with TNF-α increased ICAM-1 protein 
expression in HCAECs (Figures 5.1 and 5.2). Pre-incubation of the cells for 
16 hours with HDL isolated from prednisone-treated subjects suppressed 
ICAM-1 protein expression by 59.1±5.3% and 59.6±5.5% for the day 1 
(p<0.05) and day 5 (p<0.005) samples, respectively, compared to 35.9±8.4% 
for the HDL at 6 weeks post-treatment (Figure 5.1). HDL isolated from the 
antibiotic-treated subjects inhibited ICAM-1 protein expression by 33.1±7.1% 
at day 1, by 32.1±5.4% at day 5 and by 31.8±5.2% at 6 weeks post-
treatment (Figure 5.2). There was no statistical significance in ICAM-1 
protein expression after incubation of the cells with HDL form antibiotic-
treated subjects at 1, 5 day of treatment compared to 6 weeks post-
treatment.  
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Figure 5.1 Inhibition of ICAM-1 protein expression by HDL isolated 
from prednisone-treated subjects  
ICAM-1 protein expression in TNF-α-activated human coronary artery 
endothelial cells  (HCAECs) treated with or without HDL isolated from 
prednisone-treated COPD subjects at 1 or 5 days of treatment and 6 weeks 
post-treatment. HCAECs were pre-incubated for 16 hours with HDL (final 
protein concentration 1 mg/mL) isolated from prednisone-treated subjects at 
day 1 (D1) and day 5 (D5) of treatment, and at 6 weeks post-treatment (W6). 
The HCAECs were then stimulated for 5 hours with TNF-α, after which cell 
surface expression of ICAM-1 was determined by flow cytometry (Sections 
2.9.2-2.9.3). Results are presented as mean ± SEM.  
*p<0.05, **p<0.005  
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Figure 5.2 Inhibition of ICAM-1 protein expression by HDL isolated 
from antibiotic-treated subjects 
The effect of HDL (final protein concentration 1 mg/mL) isolated from 
antibiotic-treated subjects at day 1 (D1) and day 5 (D5) of treatment, and at 
week 6 (W6) post-treatment on ICAM-1 expression in HCAECs. HCAECs 
were pre-incubated for 16 hours with HDL then activated with TNF-α . Cell 
surface expression of ICAM-1 was quantified by flow cytometry after 5 hours 
of stimulation with TNF-α  (Sections 2.9.2-2.9.3). Results are presented as 
mean ± SEM.  
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5.3.2 Effect of pre-incubation with HDL isolated from prednisone-
treated subjects on VCAM-1 expression in TNF-α-stimulated HCAECs 
Incubation with TNF-α increased VCAM-1 protein expression in HCAECs 
(Figures 5.3 and 5.4). Pre-incubation of the cells with HDL isolated from 
prednisone-treated patients suppressed VCAM-1 protein expression by 
53.8±6.7% at day 1 (p<0.05) and by 59.7±7.2% (p>0.005) at day 5, 
compared to 22.6±6.7% for the 6 weeks post-treatment samples (Figure 5.3). 
HDL isolated from the antibiotic-treated patients inhibited VCAM-1 protein 
expression by 26.3±4.9% at day 1, by 26.2±3.8% at day 5 and by 20.9±9.0% 
in the 6 weeks post-treatment samples (Figure 5.4). The suppression of 
VCAM-1 expression by the HDL samples from the antibiotic-treated subjects 
at days 1 and 5 and 6 weeks post-treatment was not significantly different. 
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Figure 5.3  Inhibition of VCAM-1 protein expression by HDL from 
prednisone-treated subjects 
VCAM-1 protein expression in TNF-α-activated human coronary artery 
endothelial cells  (HCAECs) treated with or without HDL isolated from 
prednisone-treated COPD subjects at 1 or 5 days of treatment and 6 weeks 
post-treatment. HCAECs were pre-incubated for 16 hours with HDL (final 
protein concentration 1 mg/mL) isolated from prednisone-treated subjects at 
day 1 (D1) and day 5 (D5) of treatment, and at 6 weeks post-treatment (W6). 
HCAECs were then stimulated for an additional 5 hours with TNF-α, after 
which cell surface expression of VCAM-1 was determined by flow cytometry 
(Sections 2.9.2-2.9.3). Results are presented as mean ± SEM.  
*p<0.05, **p<0.005 
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Figure 5.4 Inhibition of VCAM-1 protein expression by HDL from 
antibiotic-treated subjects 
The effect of HDL (final protein concentration 1 mg/mL) isolated from 
antibiotic-treated subjects at day 1 (D1) and day 5 (D5) of treatment and 6 
weeks post-treatment (W6) on VCAM-1 expression. HCAECs were pre-
incubated with HDL for 16 hours, then stimulated for an additional 5 hours 
with TNF-α, after which cell surface expression of VCAM-1 was determined 
by flow cytometry (Sections 2.9.2-2.9.3). Results are presented as mean ± 
SEM.  
  
0
20
40
60
80
100
TNF-α - + + + + 
HDL - - + + + 
D1 D5 W6 
VC
AM
-1
 E
xp
re
ss
io
n 
(%
  o
f T
NF
-α
) 
	   CHAPTER FIVE 
 
 135 
5.3.3 Effect of prednisolone on ICAM-1 expression in TNF-α-stimulated 
HCAECs  
In this experiment, prednisolone at a final concentration of 1 µg/mL was used 
for incubation with HCAECs as this concentration is equivalent to what is 
observed in COPD patients treated with 50 mg of prednisone/day464. 
Incubation of HCAECs with TNF-α alone increased ICAM-1 protein 
expression (Figure 5.5). Pre-incubation of the cells with 1, 2, 5 and 20 µg/ml 
of prednisolone for 30 minutes suppressed ICAM-1 protein expression by 
1.2±0.2%, 6.1±2.5%, 7.2±3.2% and 11.8±4.1%, respectively. This modest 
reduction in ICAM-1 protein expression did not reach statistical significance.  
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Figure 5.5 Inhibition of ICAM-1 protein expression by prednisolone 
The effect of prednisolone (final concentration 1, 2, 5 and 20 µg/mL) on 
ICAM-1 expression in HCAECs.  HCAECs were pre-incubated for 30 minutes 
with prednisolone prior to activation with TNF-α for an additional 5 hours. 
ICAM-1 expression was quantified by flow cytometry as described in Section 
2.9.3.  Results are presented as mean ± SEM.  
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5.3.4 Effect of prednisolone on VCAM-1 expression in TNF-α-
stimulated HCAECs 
Incubation of HCAECs with TNF-α increased VCAM-1 protein expression 
(Figure 5.5). Pre-incubated of the HCAECs with prednisolone (final 
concentration 1-20 µg/mL, for 30 minutes) prior to activation with TNF-α 
suppressed VCAM-1 expression by up to 11.3±2.3% at a final prednisolone 
concentration of 20 µg/mL.  This reduction in VCAM-1 protein expression did 
not reach statistical significance. 
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Figure 5.6 Inhibition of VCAM-1 protein expression by prednisolone 
The effect of prednisolone (final concentration 1, 2, 5 and 20 µg/mL) on 
VCAM-1 expression in HCAECs.  HCAECs were pre-incubated for 30 
minutes with prednisolone prior to activation with TNF-α for an additional 5 
hours. Expression of VCAM-1 was quantified by flow cytometry as described 
in Section 2.9.3.  Results are presented as mean ± SEM.  
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5.4 DISCUSSION 
One measure of the anti-inflammatory properties of HDL is their ability to 
inhibit the cytokine-induced expression of adhesion molecules in cultured 
endothelial cells228. The studies described in this chapter show that HDL 
isolated from COPD subjects after 1 day and 5 days of treatment with 
prednisone inhibited endothelial expression of ICAM-1 and VCAM-1 more 
effectively than a control sample of HDL isolated 6 weeks post-treatment. 
These effects are attributed to prednisone-mediated changes to HDL 
composition, sub-population distribution and size rather than a direct effect of 
prednisolone on the inhibition of ICAM-1 and VCAM-1 as prednisolone had 
no direct effect on ICAM-1 and VCAM-1 expression in vitro.  
Corticosteroid therapy has been associated with decreased expression of 
adhesion molecules that are involved in immune reactions. Specifically, a 
single infusion of high-dose methylprednisolone (1000 mg) in the treatment 
of patients with multiple sclerosis is reported to reduce the adhesion of 
monocytes in human umbilical vein endothelial cells (HUVECs)465. Similarly, 
the anti-inflammatory effects of high-dose methylprednisolone succinate 
(1000 mg) in patients with rheumatoid arthritis have been attributed to 
reduced expression of ICAM-1 in the synovial vascular endothelium466. 
Furthermore, the treatment of mice with muscular dystrophy with 
prednisolone (0.75 mg/kg per day) for two weeks decreases vascular P-
selectin and ICAM-1 expression467. The mechanism by which prednisolone 
inhibits adhesion molecule expression is uncertain. The results in Figures 5.5 
and 5.6 have excluded the possibility of prednisolone having a direct 
influence on ICAM-1 and VCAM-1 expression. The results in this Chapter 
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and in Chapter 4 do, however, suggest that the suppression of ICAM-1 and 
VCAM-1 expression in patients treated with prednisolone may be related to 
an increase in HDL levels. 
It is well documented that HDL isolated from healthy subjects inhibit the 
cytokine-induced expression of E-selectin, ICAM-1 and VCAM-1 in 
endothelial cells growing in tissue culture in a concentration-dependent 
manner228. These experiments, as with the present study, were conducted 
with native HDL, which are known to include several sub-populations of 
particles of differing size, shape and composition. Therefore, the superior 
anti-inflammatory effects of HDL isolated from people treated with 
prednisone may be a reflection of the prednisone-mediated changes to the 
composition, sub-population distribution and size of HDL468.  
The results of Sections 4.3.2, 4.3.3 and 4.3.4 establish that large, 
cholesterol-enriched HDL2 particles that consist of apoA-I, apoA-IV and apoE 
are generated by treatment with prednisone. The results in this chapter 
suggest that these particles may have a greater anti-inflammatory potential 
than the smaller HDL3 particles that are present 6 weeks after cessation of 
treatment. The studies within this thesis show that as HDL size increases, 
the expression of the inflammatory proteins, VCAM-1 and ICAM-1 
decreases. This indicates that the larger HDL particles are more anti-
inflammatory. However, there are multiple subpopulations of overlapping 
larger HDL particles with treated patients that cannot be resolved. Therefore, 
it is not possible to attribute this populated relativity to a specific HDL 
subpopulation. 
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Studies that seek to determine whether HDL that vary in size, shape and 
composition differ in their ability to inhibit adhesion molecule expression have 
found no significant influence of particle shape, size or composition of 
apolipoproteins, cholesteryl ester and triglyceride content460. In fact, 
replacement of almost all of the cholesteryl esters in the core of rHDL with 
triglyceride had no effect on the magnitude of inhibition460. In support of 
these findings, an additional study reported that the anti-inflammatory 
potential of both rHDL and native HDL was maintained when the particles 
were enriched with the acute phase reactant, SAA469. In contrast, the 
phospholipid composition of rHDL has been reported to be a major regulator 
of adhesion molecule expression in endothelial cells461.  
The HDL in human plasma are known to transport more than 80 different 
proteins and more than 200 lipid species, as well as several microRNAs64, 
many of which could potentially regulate HDL function470. For this reason, it 
is clearly difficult to ascertain precisely how and why the anti-inflammatory 
properties of HDL were enhanced in the prednisone-treated subjects in the 
current study. However, identification of HDL sub-populations with the 
greatest anti-inflammatory potential is of considerable importance. While the 
results of the studies in this thesis suggest that large apoA-I, apoA-IV and 
apoE containing HDL may be more anti-inflammatory than smaller HDL, 
future studies will have to confirm this by evaluating the inhibitory potential of 
HDL in which the size and composition are tightly regulated.  
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EFFECT OF PREDNISONE TREATMENT ON PLASMA MARKERS OF 
INFLAMMATION 
 
6.1 INTRODUCTION 
This chapter seeks to study the effect of prednisone treatment on plasma 
inflammatory biomarkers in COPD subjects.  
Systemic inflammatory effects accompany localised and chronic responses 
in COPD subjects471. Many of the systemic manifestations of COPD are 
mediated through increased serum levels of inflammatory biomarkers472-474 
as described in Section 1.7.3. Multiple plasma chemokines, cytokines and 
adhesion molecules have been implicated in COPD prognosis. Systemic 
inflammation may also be coupled with increased oxidative stress, leading to 
the activation of circulating neutrophils471 and lymphocytes475 as well as 
increased plasma levels of acute phase proteins; CRP314,476-478, inflammatory 
cytokines; TNF-α309,310,471,478, M-CSF471 and MCP-1479-481, chemokines; IL-
1471, IL-6476-478 and IL-8309,482 and the adhesion molecules;  sICAM-1480,481 
and sVCAM-1483. The identification of soluble inflammatory proteins such as 
sICAM, sVCAM and sTNF-α in plasma corroborates the idea that the 
progression of COPD is associated with activated and elevated levels of 
inflammatory mediators in the circulation471. It is also well established that 
CRP levels correlate positively with IL-6 in COPD patients, and that both of 
these markers can be used for risk assessment in inflammatory disorders484. 
Increased plasma CRP levels in COPD patients are also associated with an 
increased risk of mortality314,485.  
Studies have shown that inflammation induced by diabetes and coronary 
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artery disease is accompanied by structural alterations in HDL that lead to 
the loss of some of their cardioprotective, and possibly their anti-diabetic 
properties486-488. During systemic inflammation, HDL become enriched in 
SAA. This is accompanied by the concomitant depletion of apoA-I, apoA-II, 
paraoxonase and LCAT489 and a decreased ability of HDL to accept 
cholesterol from cells423. However, there is no current evidence that systemic 
inflammation associated with COPD induces HDL dysfunction.   
The effects of prednisone on plasma inflammatory markers have been 
reported in a number of disorders, including COPD490,491. The mechanisms 
by which prednisone induce its anti-inflammatory actions are mainly 
attributed to the inhibition of transcription factors and a reduction in pro-
inflammatory gene transcription, as described in Section 1.8.2. Despite the 
documented increase in HDL-C levels in prednisone-treated subjects330 and 
now the associated improvement of the anti-inflammatory properties of HDL 
(Chapter 5), the impact and involvement of HDL in resolving COPD-related 
inflammation has not been investigated.  
In this chapter, the effects of short-term prednisone treatment on the plasma 
levels of inflammatory biomarkers, including CRP, MCP-1, sICAM-1 and 
sVCAM-1 in COPD subjects is investigated.  
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6.2 METHODS 
6.2.1 Measurement of plasma MCP-1   
Plasma MCP-1 levels were quantified by ELISA as outlined in Sections 2.10 
and 2.10.1.   
6.2.2 Measurement of soluble ICAM-1 and soluble VCAM-1 levels 
Plasma levels of sICAM-1 and sVCAM-1 were determined by ELISA as 
outlined in Sections 2.10 and 2.10.2.  
6.2.3 Measurement of plasma CRP levels 
Hs-CRP levels in COPD and lower respiratory tract infection subjects were 
determined by laser nephelometry as described in Section 2.10.3. 
6.2.4 Statistical analysis 
The data in this chapter are expressed as mean ± SEM. Two-tailed students’ 
t-test for paired samples was used to determine whether differences between 
values were significant. A value of p<0.05 was considered significant.  
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6.3 RESULTS 
6.3.1 Effects of prednisone therapy on inflammatory biomarkers 
Plasma CRP levels in the prednisone-treated COPD and antibiotic-treated 
groups were measured on days 1 and 5 of treatment. Plasma CRP levels 
were not measured at week 6 post-treatment due to limited sample volume. 
CRP levels in the prednisone-treated patients decreased from 72.3±26.0 
mg/L on day 1 of treatment to 11.3±2.8 mg/L on day 5 of treatment  (p<0.05). 
The antibiotic-treated patients also showed a reduction in CRP levels from 
236.5±41.9 mg/L on day 1 to 83.7±25.4 mg/L by day 5 (p<0.005) (Figure 
6.1).  
MCP-1 levels in the COPD subjects were 125.1±26.4 pg/mL on day 1 after 
commencing prednisone treatment, and 139.2±19.4 pg/mL by day 5. At six 
weeks post-treatment, the mean plasma MCP-1 level had increased to 
193.4±20.1 pg/mL (p<0.05 compared to day 1 and day 5). The antibiotic-
treated subjects had MCP-1 levels of 338.6±139.3 pg/mL on day 1 of 
treatment, 193.9±16.1 pg/mL on day 5 of treatment and 263.4±39.9 pg/mL at 
6 weeks post-treatment. The day 1 and day 5 values did not differ 
significantly from the value at 6 weeks in the antibiotic-treated subjects 
(Figure 6.2). 
The mean plasma sICAM-1 level in the COPD-treated subjects was 
228.2±19.1 ng/mL after 1 day of treatment with prednisone, and 174.1±14.2 
ng/mL at day 5. By week 6 plasma sICAM-1 levels in these individuals had 
increased to 304.8±17.0 ng/mL, (p<0.005 compared to day 1, p<0.0005 
compared to day 5). The antibiotic-treated patients had sICAM-1 levels of 
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374.9±60.3 ng/mL at day 1 and 387.4±86.5 ng/mL at day 5. At week 6, their 
plasma sICAM-1 levels had decreased to 250.5±29.1 ng/mL, (p<0.05 
compared to day 1) (Figure 6.3).  
At days 1 and 5, sVCAM-1 levels in the prednisone-treated COPD subjects 
were 478.1±43.9 and 442.2±37.0 ng/mL, respectively. At 6 weeks post-
prednisone treatment, sVCAM-1 levels had increased to 676.3±55.1 ng/mL 
(p<0.005 compared to days 1 and 5). There were no significant changes 
between days 1 (525.6±100.6 ng/mL) and 5 (468.2±68.0 ng/mL) in the 
antibiotic-treated subjects compared to 6 weeks post-treatment (476.7±45.7 
ng/mL) (Figure 6.4).  
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Figure 6.1 CRP levels in prednisone- and antibiotic-treated subjects 
Plasma CRP levels in prednisone-treated COPD subjects (black bars) (n=14) 
and antibiotic-treated, lower respiratory subjects (grey bars) (n=7) on days 1 
(D1) and 5 (D5) of treatment as determined by nephelometry (Section 
2.10.4). Results are presented as mean ± SEM.  
*p<0.05, **p<0.005 
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Figure 6.2 MCP-1 levels in prednisone- and antibiotic-treated subjects 
Plasma MCP-1 levels in prednisone-treated (black bars) (n=8) and antibiotic-
treated (grey bars) (n=6) subjects on days 1 (D1) and 5 (D5) of treatment 
and 6 weeks post-treatment (W6) as determined by ELISA (Sections 2.10 
and 2.10.1). Results are presented as mean ± SEM.  
*p<0.05 
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Figure 6.3 sICAM-1 levels in prednisone- and antibiotic-treated 
subjects 
Plasma sICAM-1 levels in prednisone-treated (black bars) (n=8) and 
antibiotic-treated (grey bars) (n=6) subjects on days 1 (D1) and 5 (D5) of 
treatment and 6 weeks post-treatment (W6) as determined by ELISA 
(Sections 2.10 and 2.10.3). Results are presented as mean ± SEM.  
*p<0.05, **p<0.005, ***p<0.0005 
  
0
100
200
300
400
500
Prednisone
Non- steroidal
D 1 D 5 W 6 D 1 D 5 W 6 
sI
C
A
M
-1
 (n
g/
m
L)
  
** 
*** 
* 
	   CHAPTER SIX 
 
 151 
 
Figure 6.4 sVCAM-1 levels in prednisone- and antibiotic-treated 
subjects 
Plasma sVCAM-1 levels in prednisone-treated (black bars) (n= 8) and 
antibiotic-treated (grey bars) (n=6) subjects on days 1 (D1) and 5 (D5) of 
treatment and 6 weeks post-treatment (W6) as determined by ELISA 
(Sections 2.10 and 2.10.3). Results are presented as mean ± SEM.  
**p<0.005, ***p<0.0005 
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6.4 DISCUSSION 
This study establishes that treatment with high-dose prednisone results in a 
rapid reduction in circulating levels of the inflammatory biomarkers MCP-1, 
sICAM-1 and sVCAM-1 in COPD subjects.  
Increased plasma MCP-1 levels are correlated with COPD492 and have also 
been reported in subjects with lower respiratory tract infections493,494. During 
an inflammatory response MCP-1 activates both monocytes and T 
lymphocytes, and acts primarily as a chemoattractant molecule495. MCP-1 
functions in the initiation and development of atherosclerosis by recruiting 
monocytes into the subendothelial cell space496,497 Prednisone treatment has 
been shown to be associated with a rapid reduction in serum MCP-1 
levels490,498, which has been confirmed by the current study.   
Soluble ICAM-1499-501 and soluble VCAM-1502 levels are increased in the 
serum of patients with pulmonary inflammation as a consequence of chronic 
lung disease, and have been suggested as biomarkers for disease activity 
and prognosis. Prednisone treatment has been reported to reduce sICAM-1 
levels in patients with COPD and autoimmune disorders491,503. This is 
consistent with the results of the present study. The higher level of sICAM-1 
at day 1 compared to 6 weeks post-antibiotic treatment in this study is most 
probably related to the inflammatory status of the patients. Previous studies 
have demonstrated that antibiotic treatment does not affect soluble 
endothelium-derived adhesion molecule levels504. This was also confirmed in 
the present study  
High serum CRP levels are considered as a prognostic indicator of the 
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severity of COPD505 and lower respiratory tract infections506. Serum levels of 
>50 mg/L in people with COPD are associated with an increased incidence 
of disease exacerbation and hospitalisation507. CRP levels >100 mg/L in 
subjects with lower respiratory tract infections are also associated with an 
increased risk of mortality506. The CRP levels in both the COPD and lower 
respiratory tract infection subjects decreased significantly from day 1 to day 5 
of treatment, which is reflective of the improved inflammatory status in these 
patients.  
In conclusion, prednisone is effective in suppressing systemic inflammatory 
proteins in COPD subjects. However, the involvement of HDL in this process 
is yet to be investigated.  
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7.1 GENERAL DISCUSSION  
The studies outlined in this thesis extend our understanding of the effects of 
prednisone on plasma lipid and lipoprotein profiles and HDL function in 
subjects with COPD. In particular, the major findings have advanced 
knowledge of prednisone-induced changes in HDL size, composition and 
sub-population distribution, and demonstrate that these changes translate 
into improvements in the anti-inflammatory properties of HDL.  
The results in Chapter 3 confirm and extend current understanding of the 
effects of high-dose, short-term prednisone administration on plasma lipid 
and lipoprotein levels. Acute corticosteroid administration has previously 
been reported to significantly increase plasma HDL-C and apoA-I 
levels18,20,21, which was confirmed in the present study. Understanding of the 
effect of corticosteroids on other lipids and lipoproteins has also been 
extended with the results showing that treatment of COPD subjects with 
prednisone decreases triglyceride levels but has no effect on apoA-II, apoB, 
total cholesterol or phospholipid levels.  
The increase in plasma HDL-C and apoA-I levels in prednisone-treated 
subjects may be due to both increased production and decreased catabolism 
of HDL particles. Several possibilities have been suggested, for the increase 
in HDL-C levels, including reduced clearance of HDL via the hepatic SR-B1 
receptor508-510, decreased activity of hepatic triglyceride lipase511, 
corticosteroid-stimulated liver production of nascent HDL409, decreased 
CETP activity411 and a corticosteroid-induced increase in enterohepatic 
cycling of bile acids which may lead to increased biliary secretion of 
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cholesterol and phospholipids512. The underlying mechanisms of the 
prednisone-induced increase in plasma apoA-I levels have previously been 
reported to be due to increased hepatic apoA-I gene transcription404-407.  
Subjects with COPD are reported to have significant decreases in plasma 
apoA-I levels513.   Previous studies have also shown that deletion of the 
apoA-I gene can increase airway hyper-responsiveness and decrease 
pulmonary artery vasodilation in mice514. The therapeutic benefit of 
increasing apoA-I levels in subjects with pulmonary inflammation has been 
the focus of many other studies. In studies using the apoA-I mimetic peptide, 
L-4F, anti-inflammatory effects in acute respiratory distress syndrome 
subjects have been attributed to an inhibition of endotoxin activity and 
preservation of HDL anti-oxidant activity515. ApoA-I has also been found to 
effectively protect against LPS-induced acute lung injury and endotoxemia in 
mice via a mechanism that is attributed to an inhibition of inflammatory 
cytokine release from macrophages516. Taken together these findings 
support the proposition that increasing the concentration of apoA-I may 
attenuate pulmonary inflammation.   
To further characterise the prednisone-induced changes to HDL and its 
components, the size, composition and sub-population distribution of HDL 
from COPD subjects was determined in Chapter 4. Prednisone therapy 
increased HDL size and the total cholesterol content of the particles. This 
was associated with a shift in the sub-population distribution to larger apoA-I-
containing HDL particles, as well as the appearance of large apoA-IV- and 
apoE-containing HDL. These results were associated with a concomitant 
reduction in CETP activity.  
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When the results of Chapter 4 are considered in conjunction with the results 
of Chapter 3, it is most likely that the increase in the size of HDL is a 
consequence of an increase in the protein and cholesterol content of the 
particles, generating large structurally unstable particles that are depleted of 
surface constituents. The viability of these particles is dependent on the 
incorporation of additional apolipoproteins, such as apoE or apoA-IV, to the 
particle surface432,517.  
This is the first study to highlight changes in the sub-population distribution of 
HDL in COPD subjects. The existence of large apoA-I, apoA-IV and apoE 
containing HDL particles during prednisone therapy is of considerable 
interest. Analyses of HDL sub-population distribution as a predictor of 
cardiovascular events have found that large, α-migrating HDL are the best 
negative predictor of recurrent cardiovascular events, while smaller α-
migrating HDL positively predict events518-520. Interestingly, both CETP-
deficient patients192,521 and individuals treated with a CETP inhibitor522 have 
increased plasma concentrations of apoE-containing HDL521,523. While the 
anti-inflammatory and anti-oxidant properties of lipid-free apoE59,521,524 and 
apoA-IV117,525,526 have been well-documented, there are no reports of the 
translation of these properties into HDL-associated apoE and apoA-IV 
particles. This is mainly attributed to difficulties in isolating HDL particles 
without causing the dissociation of apoA-IV and apoE. Notwithstanding the 
technical challenges of addressing these issues, the results in Chapter 4 
showing that prednisone treatment increases HDL size, and that these larger 
particles are enriched in apoA-IV and apoE. This raises the possibility that 
the acquisition of apoA-IV and apoE by the HDL in the prednisone-treated 
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subjects may have been responsible for the enhanced anti-inflammatory 
properties that were observed in Chapter 5.  
The mechanism by which prednisone induces changes in plasma lipid profile 
is not known. On the basis of the studies in this thesis, the changes in HDL 
size and composition during prednisone treatment are associated with a 
decrease in CETP activity as shown in Chapter 4. There is a growing body of 
evidence to support the decrease in CETP activity by 
glucocorticoids411,450,453. However, other mechanisms such as an increase in 
hepatic synthesis of apoA-I, a reduction of hepatic lipase activity or 
decreased clearance of HDL via the hepatic SR-B1 receptor should all be 
investigated in future work. It is possible that prednisone, as a non-specific 
multi-functional drug, may have its effects on plasma lipids through a 
combination of all of these mechanisms in vivo.  
The experiments in Chapter 5 showed that HDL from prednisone-treated 
subjects have a greater capacity to suppress the cytokine-induced increase 
in ICAM-1 and VCAM-1 expression in HCAECs. Additional experiments 
further established that the ability of HDL to inhibit ICAM-1 and VCAM-1 
expression in endothelial cells could not be explained by the presence of 
prednisolone in the HDL sample. These results therefore suggest that the 
ability of prednisone treatment to decrease adhesion molecule expression in 
vitro may in be mediated, at least in part, by the anti-inflammatory properties 
of HDL. As an extension of this work, it would be worth exploring other 
functional properties of HDL from prednisone-treated subjects such as their 
ability to inhibit oxidation, thrombosis, apoptosis and improve glucose 
metabolism.    
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The results in Chapter 6 show that high-dose prednisone treatment rapidly 
decrease circulating levels of the inflammatory markers MCP-1, sICAM-1 
and sVCAM-1 in COPD subjects. The mechanism by which prednisone 
inhibits these plasma inflammatory markers is currently unknown. Given that 
there is a strong body of evidence that has documented specific mechanisms 
by which HDL can decrease these inflammatory markers, it seems 
reasonable to suggest that the effects of prednisone on plasma inflammatory 
proteins may be partially mediated by the anti-inflammatory actions of HDL. 
For instance, HDL-associated lysosphingolipids have been reported to inhibit 
NAD(P)H oxidase- dependent MCP-1 production527. There is also evidence 
that HDL have the ability to reduce cytokine-induced expression of 
endothelial cell, ICAM-1 and VCAM-1 expression228 via a mechanism that 
involves HDL-mediated upregulation of DHCR24 expression528. Future 
studies are required to test this hypothesis.  
7.2 LIMITATIONS OF THE STUDY 
This study has some shortcomings. It is an open-label, non-randomised 
study of a small number of subjects with each subject acting as his or her 
own control. In an attempt to reduce confounding factors, subjects with 
hypercholesterolaemia, hyperlipidaemia and hypertriglyceridaemia were 
excluded from the study. It therefore follows that the subjects that were 
recruited for this project may not be truly representative of COPD subjects. 
Furthermore, acute infections such as respiratory tract infections in the 
control group can alter HDL metabolism, and may decrease HDL-C levels529.  
Despite this, the results are intriguing and clearly support the need for larger 
studies in the future.  
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While the COPD/prednisone study is a well-designed model for the 
assessment of HDL levels and function, a great deal of additional work 
needs to be carried out to effectively characterise the structural and 
functional properties of each HDL sub-population530.  
7.3 CONCLUSION  
The studies outlined in this thesis have provided a detailed characterisation 
and analysis of sub-population distribution and anti-inflammatory properties 
of HDL in prednisone-treated COPD subjects. The results show that 
prednisone administration significantly increases plasma HDL-C levels, 
increases HDL size, and alters the composition of HDL possibly by inhibiting 
CETP.  The link between these changes and the improvement in the anti-
inflammatory properties of HDL remains to be determined. Nevertheless, 
these results do raise the intriguing possibility that the anti-inflammatory 
actions of prednisone may be partially mediated by HDL and that therapeutic 
interventions that increase HDL levels, such as the inhibition of CETP, may 
be beneficial for COPD subjects. This possibility is worthy of further 
exploration with a focus on understanding the effects of a range of HDL-
raising strategies on the sub-population distribution and other beneficial 
functions of HDL in people with COPD.  
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